[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 147
1. Kim Y, Kang MS, Kim CW, Sung R, Ko YH: CD4+CD56+ lineage negative hematopoietic neoplasm: so called blastic NK cell lymphoma. J Korean Med Sci; 2005 Apr;20(2):319-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patients were 3 men and one woman.
  • Three patients had skin lesions, at initial presentation in two patients and during the course of disease in other patient.
  • Histologically, tumors consisted of monotonous medium to large blastoid cells showing no necrosis, angiocentric growth or epidermotrophism.
  • All four tumors were CD4+ and CD56+.
  • All tumors did not express myeloperoxidase.
  • In one patient, tumor cells arranged in Homer-Wright type pseudorosette and expressed terminal deoxynucleotidyl transferase(TdT).
  • Despite the standard lymphoma chemotherapy, the tumors, except one lost during follow-up, progressed and relapsed.
  • The patients died 8-60 months after diagnosis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2001 Mar;38(3):250-70 [11260307.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):41-50 [11789729.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):153-60 [11328295.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):168-76 [11488062.001]
  • [Cites] J Immunol. 2001 Oct 1;167(7):3635-41 [11564776.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):225-8 [11722437.001]
  • [Cites] Ann Hematol. 2001 Dec;80(12):752-4 [11797118.001]
  • [Cites] Am J Dermatopathol. 2002 Feb;24(1):72-5 [11803287.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1556-63 [11861268.001]
  • [Cites] Cancer. 2002 May 1;94(9):2401-8 [12015765.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):852-62 [12131152.001]
  • [Cites] J Korean Med Sci. 2002 Dec;17(6):833-9 [12483012.001]
  • [Cites] Blood. 2003 Jun 15;101(12):5007-9 [12576313.001]
  • [Cites] Haematologica. 2003 Aug;88(8):941-55 [12935983.001]
  • [Cites] Am J Hematol. 2003 Sep;74(1):46-51 [12949889.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1366-74 [14508398.001]
  • [Cites] Br J Dermatol. 2003 Oct;149(4):869-76 [14616384.001]
  • [Cites] Am J Hematol. 1994 Dec;47(4):278-82 [7526680.001]
  • [Cites] Am J Surg Pathol. 1997 Feb;21(2):242-8 [9042293.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1223-30 [9331296.001]
  • [Cites] Histopathology. 1998 Dec;33(6):547-53 [9870150.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):67-75 [9916920.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):991-2 [10435571.001]
  • [Cites] J Immunol. 2000 Feb 15;164(4):1730-3 [10657617.001]
  • [Cites] Int J Hematol. 2000 Dec;72(4):477-83 [11197216.001]
  • [Cites] Pathol Int. 2001 Jan;51(1):55-9 [11148466.001]
  • [Cites] Virchows Arch. 2001 Mar;438(3):271-9 [11315624.001]
  • (PMID = 15832009.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD56
  • [Other-IDs] NLM/ PMC2808614
  •  go-up   go-down


2. Yamamoto M, Oshiro S, Tsugu H, Hirakawa K, Ikeda K, Soma G, Fukushima T: Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha. Anticancer Res; 2002 Jul-Aug;22(4):2447-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha.
  • BACKGROUND: This study assesses the safety, tolerance and preliminary efficacy of combined treatment with carboplatin, etoposide and recombinant human mutant tumor necrosis factor-alpha (TNF-SAM2) for recurrent malignant supratentorial astrocytomas at first relapse.
  • Treatment was repeated every 8 to 12 weeks.
  • RESULTS: Ten patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosourea (ranimustine: MCNU) for malignant astrocytomas received this regimen for up to four cycles.
  • Three patients with anaplastic astrocytomas, one patient with anaplastic oligoastrocytoma and 6 patients with glioblastomas (3 men and 7 women), aged 27 to 69 years, were eligible and were evaluated for response and toxicity.
  • Of 9 evaluable patients, three (33%), including one glioblastoma, partially responded to the treatment (PR) with time to tumor progression (TTP) of 231, 121 and 57 weeks, respectively.
  • Two patients had stable disease (SD), while 4 glioblastomas (44%) had progressive disease (PD) with TTP values of 11, 15, 6 and 12 weeks, respectively.
  • CONCLUSION: These results suggest that combined therapy with carboplatin, etoposide and recombinant mutant TNF-alpha in this patient population seems to be safe and acceptable and may benefit those with recurrent anaplastic astrocytomas.
  • These intriguing clinical observations warrant a properly stratified randomized trial to determine whether this approach can provide therapeutic benefits and improve survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Supratentorial Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adult. Aged. Brain / pathology. Carboplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Patient Selection. Recombinant Proteins / administration & dosage. Treatment Outcome

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174942.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


3. Maurer M, Riesen W, Muser J, Hulter HN, Krapf R: Neutralization of Western diet inhibits bone resorption independently of K intake and reduces cortisol secretion in humans. Am J Physiol Renal Physiol; 2003 Jan;284(1):F32-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A Western-type diet is associated with osteoporosis and calcium nephrolithiasis.
  • However, it is not known whether the dietary acid load acts directly or indirectly (i.e., via endocrine changes) on bone metabolism.
  • The effects of neutralization of dietary acid load (equimolar amounts of NaHCO(3) and KHCO(3) substituted for NaCl and KCl) in nine healthy subjects (6 men, 3 women) under metabolic balance conditions on calcium balance, bone markers, and endocrine systems relevant to bone [glucocorticoid secretion, IGF-1, parathyroid hormone (PTH)/1,25(OH)(2) vitamin D and thyroid hormones] were studied.
  • [MeSH-major] Acidosis / drug therapy. Bone Resorption / drug therapy. Carbonates / administration & dosage. Hydrocortisone / secretion. Potassium / administration & dosage. Potassium, Dietary / administration & dosage. Sodium Bicarbonate / administration & dosage
  • [MeSH-minor] Acid-Base Equilibrium / drug effects. Adrenocorticotropic Hormone / blood. Adult. Circadian Rhythm. Female. Food Habits. Humans. Male. Osteoporosis / blood. Osteoporosis / diet therapy. Osteoporosis / drug therapy. Western World

  • MedlinePlus Health Information. consumer health - Potassium.
  • Hazardous Substances Data Bank. SODIUM BICARBONATE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. POTASSIUM CARBONATE .
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12388390.001).
  • [ISSN] 1931-857X
  • [Journal-full-title] American journal of physiology. Renal physiology
  • [ISO-abbreviation] Am. J. Physiol. Renal Physiol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbonates; 0 / Potassium, Dietary; 8MDF5V39QO / Sodium Bicarbonate; 9002-60-2 / Adrenocorticotropic Hormone; BQN1B9B9HA / potassium carbonate; RWP5GA015D / Potassium; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


Advertisement
4. Díez JJ, Iglesias P: Somatostatin analogs in the treatment of medullary thyroid carcinoma. J Endocrinol Invest; 2002 Oct;25(9):773-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin analogs in the treatment of medullary thyroid carcinoma.
  • The medical therapy for advanced or metastatic medullary thyroid carcinoma has not been fully established.
  • Somatostatin analogs have been used with variable success in the therapy of a few patients with medullary thyroid carcinoma.
  • In the present study, we evaluated the effects of somatostatin analog therapy on calcitonin (ct) and carcinoembryonic antigen in patients with advanced medullary thyroid carcinoma.
  • Five patients (2 men and 3 women, aged 35-57 yr) with post-operative recurrent medullary thyroid carcinoma received somatostatin analog therapy for 12 weeks.
  • Serum samples for ct and carcinoembryonic antigen were obtained at 0, 1, 2, 4, 8 and 12 weeks of therapy.
  • Therapy was well-tolerated in general, with minimal side-effects.
  • One patient died after the first month of therapy because of advanced disease.
  • Another patient showed normalization of his ct and carcinoembryonic antigen concentrations at the second week of therapy, maintaining elevated values thereafter.
  • One patient with positive (111)In-pentetreotide scan, showed no uptake after somatostatin analog therapy.
  • In conclusion, therapy with different formulations of octreotide and lanreotide does not seem to modify serum concentrations of ct and carcinoembryonic antigen in patients with recurrent medullary thyroid carcinoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Medullary / drug therapy. Octreotide / therapeutic use. Peptides, Cyclic / therapeutic use. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Adult. Calcitonin / blood. Carcinoembryonic Antigen / blood. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 1987 Oct;22(8):938-42 [2891186.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):402-8 [8625251.001]
  • [Cites] Henry Ford Hosp Med J. 1989;37(3-4):151-3 [2576951.001]
  • [Cites] Cancer. 2001 May 1;91(9):1797-808 [11335906.001]
  • [Cites] Q J Nucl Med. 1995 Dec;39(4 Suppl 1):134-6 [9002772.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):246-54 [8532003.001]
  • [Cites] Ann Endocrinol (Paris). 1989;50(6):483-8 [2635843.001]
  • [Cites] J Clin Endocrinol Metab. 1987 Jun;64(6):1313-9 [2883196.001]
  • [Cites] Clin Nucl Med. 1988 Apr;13(4):260-3 [2897264.001]
  • [Cites] Horm Metab Res. 1989 Oct;21(10):584-6 [2807148.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jul;83(7):2417-20 [9661621.001]
  • [Cites] Surgery. 1986 Dec;100(6):962-70 [2431492.001]
  • [Cites] Horm Metab Res. 1988 Dec;20(12):773-5 [2906036.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):1114-8 [8780551.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Aug;33(2):261-9 [1977536.001]
  • [Cites] Med Klin (Munich). 1995 Feb 15;90(2):63-6 [7708002.001]
  • [Cites] Horm Metab Res Suppl. 1993;27:44-7 [8330871.001]
  • [Cites] Yale J Biol Med. 1992 Sep-Oct;65(5):505-18; discussion 531-6 [1364090.001]
  • [Cites] Neth J Med. 1992 Jun;40(5-6):240-3 [1436261.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):983-8 [10720027.001]
  • [Cites] Clin Endocrinol (Oxf). 1992 Feb;36(2):183-6 [1568350.001]
  • (PMID = 12398235.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Carcinoembryonic Antigen; 0 / Peptides, Cyclic; 0G3DE8943Y / lanreotide; 51110-01-1 / Somatostatin; 9007-12-9 / Calcitonin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


5. Spiliotis J, Tentes AA, Vaxevanidou A, Korakianitis OS, Rogdakis A, Mirelis CG, Datsis AC, Kekelos S: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. Preliminary results and cost from two centers in Greece. J BUON; 2008 Apr-Jun;13(2):205-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. Preliminary results and cost from two centers in Greece.
  • PURPOSE: To report our preliminary experience in the combined treatment of peritoneal carcinomatosis (PC) using cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC).
  • RESULTS: Twenty-four patients (3 men and 21 women, mean age 60 years) were treated.
  • The mean duration of the procedure was 7.83 h (range 5 -12.30).
  • CONCLUSION: Our preliminary data suggest that the combined treatment of cytoreduction plus HIPEC for PC is associated with acceptable mortality and morbidity and offers an improved survival in these patients.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / economics. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Colonic Neoplasms / drug therapy. Colonic Neoplasms / economics. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Colonic Neoplasms / therapy. Female. Humans. Infusions, Parenteral. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / economics. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Ovarian Neoplasms / therapy. Prognosis. Prospective Studies. Stomach Neoplasms / drug therapy. Stomach Neoplasms / economics. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery. Stomach Neoplasms / therapy. Survival Rate. Treatment Outcome. Uterine Neoplasms / drug therapy. Uterine Neoplasms / economics. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery. Uterine Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18555466.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Greece
  •  go-up   go-down


6. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, Gangl A, Ferenci P: Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology; 2003 Jan;37(1):60-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early interferon (IFN) therapy prevents viral persistence in acute hepatitis C, but in view of the resulting costs and morbidity patients who really need therapy have to be identified.
  • Twelve consecutive patients with acute hepatitis C (9 women, 3 men, mean age: 39.5 +/- 18.8 y, genotype 1: 7, genotype 3a: 3, 2 could not be genotyped) were studied.
  • The sources of infection were medical procedures in 6, sexual transmission in 3, and intravenous drug abuse in 3 patients.
  • The time from infection to clinical symptoms was 43.3 +/- 8.6 (mean +/- SD) days.
  • The time from exposure to HCV-RNA negativity was 77.4 +/- 25.3 and from the first symptoms was 34.7 +/- 22.1 days.
  • Two of them became sustained responders to treatment initiated after a 6-week observation period.
  • The 2 remaining patients were not treated (one because of contraindications for IFN, the other declined therapy) and are still HCV-RNA positive.
  • IFN therapy appears only needed in patients who fail to clear the virus within 35 days after onset of symptoms.
  • By this approach, IFN therapy was not necessary in two thirds of patients with acute hepatitis C.
  • [MeSH-major] Hepacivirus / genetics. Hepatitis C / diagnosis. Hepatitis C / virology. Viral Load
  • [MeSH-minor] Acute Disease. Adult. Age Factors. Alanine Transaminase / blood. Female. Genotype. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Prospective Studies. RNA, Viral / analysis

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2003 Jun;37(6):1495-6; author reply 1496 [12774030.001]
  • (PMID = 12500189.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


7. Dayi SU, Kasikcioglu H, Uslu N, Tartan Z, Uyarel H, Terzi S, Hobikoglu G, Okmen E, Cam N: Influence of weight loss on myocardial performance index. Heart Vessels; 2006 Mar;21(2):84-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 18 obese patients (3 men, 15 women, mean age 49.6 +/- 5.5 years, body mass index [BMI] >30 kg/m(2)) were investigated in the study.
  • All patients were treated with a multidisciplinary approach consisting of a hypocaloric diet and orlistat therapy (120 mg three times daily), and all of them underwent two-dimensional and Doppler echocardiographic examination two times before starting the study and after a period of weight loss.
  • Using echo-Doppler methods, ejection fraction, peak velocities of early (E) and late (A) diastolic filling, the E/A ratio, deceleration time (DT), isovolumic contraction time (IVCT), isovolumic relaxation time, ejection time, and MPI were measured.
  • The MPI was obtained by subtraction ejection time from the interval between cessation and onset of the mitral flow.
  • Compared with baseline, after weight loss the E/A ratio of 1.01 +/- 0.22 before treatment increased to 1.17 +/- 0.26 (P = 0.012), left ventricular mass index decreased from 88 +/- 23 to 82 +/- 19 g/m(2) (P = 0.028), IVCT from 71 +/- 20 to 53 +/- 30 ms (P = 0.004), DT from 233.65 +/- 38.14 to 196.72 +/- 47.73 s (P = 0.004), and MPI from 0.63 +/- 0.13 to 0.50 +/- 0.13 (P = 0.0001).
  • [MeSH-minor] Anti-Obesity Agents / therapeutic use. Body Mass Index. Diet, Reducing. Echocardiography, Doppler. Female. Humans. Lactones / therapeutic use. Male. Middle Aged. Prognosis. Prospective Studies. Statistics, Nonparametric. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Weight Control.
  • Hazardous Substances Data Bank. ORLISTAT .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Echocardiogr. 1997 Mar;10 (2):169-78 [9083973.001]
  • [Cites] Jpn Circ J. 2001 Jul;65(7):637-42 [11446498.001]
  • [Cites] Am J Cardiol. 1999 Nov 1;84(9):1127-9, A11 [10569684.001]
  • [Cites] Diabetes Care. 2004 Jan;27(1):47-52 [14693965.001]
  • [Cites] Am J Cardiol. 1999 Mar 1;83(5):728-34 [10080427.001]
  • [Cites] Am Heart J. 1992 Sep;124(3):694-9 [1514498.001]
  • [Cites] J Am Coll Cardiol. 1996 Sep;28(3):658-64 [8772753.001]
  • [Cites] Am J Cardiol. 1998 Nov 1;82(9):1071-6 [9817484.001]
  • [Cites] Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):325-34 [3975428.001]
  • [Cites] Eur Heart J. 2000 Jan;21(2):94-6 [10637079.001]
  • [Cites] J Am Coll Cardiol. 1998 Oct;32(4):865-75 [9768704.001]
  • [Cites] Circulation. 1957 Aug;16(2):179-87 [13447161.001]
  • [Cites] J Am Soc Echocardiogr. 2002 Sep;15(9):864-8 [12221401.001]
  • [Cites] J Cardiol. 1995 Dec;26(6):357-66 [8558414.001]
  • [Cites] Circulation. 1997 Nov 4;96(9):3248-50 [9386201.001]
  • [Cites] Am J Cardiol. 1991 Jul 1;68(1):95-8 [1829321.001]
  • [Cites] Heart. 2003 Oct;89(10):1152-6 [12975404.001]
  • [Cites] Obes Res. 2000 Jan;8(1):49-61 [10678259.001]
  • [Cites] Am J Cardiol. 2000 Jan 1;85(1):19-25 [11078230.001]
  • [Cites] Eur Heart J. 2000 Nov;21(22):1888-95 [11052862.001]
  • [Cites] N Engl J Med. 2002 Aug 1;347(5):305-13 [12151467.001]
  • [Cites] Eur Heart J. 2004 Dec;25(24):2220-5 [15589639.001]
  • [Cites] J Am Soc Echocardiogr. 2000 May;13(5):379-84 [10804435.001]
  • [Cites] Hellenic J Cardiol. 2005 Jan-Feb;46(1):52-8 [15807396.001]
  • [Cites] Heart Vessels. 2004 Mar;19(2):68-74 [15042390.001]
  • (PMID = 16550308.001).
  • [ISSN] 0910-8327
  • [Journal-full-title] Heart and vessels
  • [ISO-abbreviation] Heart Vessels
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Obesity Agents; 0 / Lactones; 95M8R751W8 / orlistat
  •  go-up   go-down


8. Hamada H, Irifune K, Ito R, Sakai K, Kadowaki T, Katayama H, Abe M, Shiode M, Nishimura K, Higaki J: Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer. Gan To Kagaku Ryoho; 2007 Aug;34(8):1235-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.
  • This pilot study evaluated the efficacy and toxicity of docetaxel and cisplatin as second-line chemotherapy for patients with advanced NSCLC.
  • PATIENTS AND METHODS: Eleven patients with advanced NSCLC who had no response to platinum-based treatment or had recurrence after a partial response were enrolled (2 stage III B, 9 stage IV; 8 men, 3 women).
  • Four weeks or more after the end of previous therapy, all 11 patients received docetaxel 60 mg/m2 and cisplatin 80 mg/m2 on day 1 every four weeks.
  • RESULTS: Two patients (18.2%) achieved a partial response,five (45.4%) patients had stable disease, and four (36.4%) patients showed progressive disease after initiation of second-line therapy.
  • Median time to disease progression was 101 days, and the one-year survival rate was 36.4%.
  • CONCLUSIONS: The regimen of docetaxel and cisplatin has reasonable efficacy with moderate toxicity as second-line chemotherapy for patients with previously treated, advanced NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Drug Administration Schedule. Female. Humans. Leukopenia / chemically induced. Male. Middle Aged. Neutropenia / chemically induced. Survival Rate. Taxoids / administration & dosage. Taxoids / adverse effects


9. Malagón HD, Valdez AM, Moran CA, Suster S: Germ cell tumors with sarcomatous components: a clinicopathologic and immunohistochemical study of 46 cases. Am J Surg Pathol; 2007 Sep;31(9):1356-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germ cell tumors with sarcomatous components: a clinicopathologic and immunohistochemical study of 46 cases.
  • The clinicopathologic features of 46 patients with germ cell tumors with sarcomatous components (GCTSC) involving either the primary site or their metastases were studied.
  • There were 43 men and 3 women aged 17 to 74 years.
  • Twenty-three tumors arose in the mediastinum, 2 in the retroperitoneum, and 21 in the gonads.
  • The germ cell component consisted of pure mature or immature teratoma (23 cases), teratoma mixed with other seminomatous or nonseminomatous components (17), pure seminoma (2), intratubular germ cell neoplasia (1), and yolk sac tumor (1).
  • All patients were treated by cisplatinum-based chemotherapy plus other agents followed by surgery.
  • Thirty-two of 40 patients either died of tumor (25/40; 62.5%) or were alive with advanced, progressive disease (7/40; 17.5%), and only 8/40 (20%) were alive and free of disease between 5 to 40 months (mean=18 mo).
  • [MeSH-major] Immunohistochemistry. Mediastinal Neoplasms / diagnosis. Neoplasms, Germ Cell and Embryonal / diagnosis. Ovarian Neoplasms / diagnosis. Retroperitoneal Neoplasms / diagnosis. Sarcoma / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Orchiectomy. Ovariectomy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721191.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Guenifi W, Rais M, Gasmi A, Ouyahia A, Boukhrissa H, Mechakra S, Houari M, Nouasria B, Lacheheb A: [Neurobrucellosis: description of 5 cases in Setif Hospital, Algeria]. Med Trop (Mars); 2010 Jun;70(3):309-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Neurobrucellose: 5 observations à l'hôpital de Sétif, Algérie.
  • There were 2 women and 3 men with a mean age of 20 years.
  • Definitive diagnosis was based on isolation of bacteria from a blood specimen in 1 case and detection of antibodies in blood and cerebrospinal fluid in 4.
  • All patients were treated using a combination of 3 of the following 4 drugs: doxycycline, rifampicine, cotrimoxazole and aminoside.
  • Treatment was associated with corticosteroid therapy in 3 cases.
  • DISCUSSION: Neurobrucellosis can affect any part of the nervous system and can mimic any neurological disease.
  • Early detection and treatment is the only predictor of favorable outcome of neurobrucellosis, but there is no standardized treatment protocol.
  • Neurobrucellosis should be included in differential diagnosis for any patient presenting central or peripheral neurological manifestations especially in endemic zones.
  • [MeSH-major] Brucellosis / diagnosis. Central Nervous System Bacterial Infections / diagnosis
  • [MeSH-minor] Adolescent. Adult. Algeria / epidemiology. Anti-Bacterial Agents / therapeutic use. Developing Countries. Diagnosis, Differential. Drug Therapy, Combination. Early Diagnosis. Female. Glucocorticoids / therapeutic use. Humans. Incidence. Male. Meningoencephalitis / diagnosis. Polyneuropathies / diagnosis. Radiculopathy / diagnosis. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20734609.001).
  • [ISSN] 0025-682X
  • [Journal-full-title] Médecine tropicale : revue du Corps de santé colonial
  • [ISO-abbreviation] Med Trop (Mars)
  • [Language] fre
  • [Publication-type] English Abstract; Letter
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Glucocorticoids
  •  go-up   go-down


11. Wang C, Swerdloff R, Kipnes M, Matsumoto AM, Dobs AS, Cunningham G, Katznelson L, Weber TJ, Friedman TC, Snyder P, Levine HL: New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab; 2004 Aug;89(8):3821-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.
  • A new mucoadhesive testosterone buccal system (Striant), 30 mg testosterone (T), was applied twice daily in 82 hypogonadal men for 3 months.
  • The mean percentage of time over a 24-h period that total serum T concentrations were above the lower limit of adult male range was 80.1%.
  • During treatment, mean serum 5alpha-dihydrotestosterone, free T, and estradiol concentrations paralleled serum T.
  • T pharmacokinetics were not significantly affected by body mass index, age, food or beverage, gum abnormalities, or medications known to cause dry mouth.
  • Except for three subjects, the gum adverse effects occurred early during treatment, did not cause interruption of treatment, and resolved rapidly and completely.
  • The T buccal system is a novel T formulation that offers a safe, effective, and convenient alternative to existing formulations for physiological T replacement therapy in hypogonadal men.
  • [MeSH-major] Androgens / administration & dosage. Androgens / blood. Cheek. Drug Delivery Systems. Hypogonadism / blood. Hypogonadism / drug therapy. Testosterone / administration & dosage. Testosterone / blood
  • [MeSH-minor] Adult. Aged. Aging / blood. Body Mass Index. Dihydrotestosterone / blood. Drug Administration Schedule. Estradiol / blood. Follicle Stimulating Hormone / blood. Humans. Luteinizing Hormone / blood. Male. Middle Aged. Mouth Mucosa. Osmolar Concentration. Patient Acceptance of Health Care. Patient Compliance. Tissue Adhesives

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15292312.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01RR00425
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Tissue Adhesives; 08J2K08A3Y / Dihydrotestosterone; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


12. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B: Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology; 2006 May;67(5):1043-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
  • OBJECTIVES: Recurrent ischemic priapism describes a disorder of repeated episodes of prolonged penile erection that frequently leads to devastating complications of erectile tissue damage and erectile dysfunction.
  • A mechanistic role for dysregulated phosphodiesterase 5 (PDE5) in the deranged smooth muscle response of the corpus cavernosum of the penis offers new understanding about the pathogenesis of the disorder and suggests that PDE5 may serve as a molecular target for its treatment and prevention.
  • We explored the use of PDE5 inhibitors to treat recurrent priapism, based on the hypothesis that the erection regulatory function of PDE5 would be regularized by this treatment and protect against further episodes.
  • METHODS: We administered PDE5 inhibitors using a long-term therapeutic regimen to 3 men with sickle cell disease-associated priapism recurrences and 1 man with idiopathic priapism recurrences.
  • RESULTS: Long-term PDE5 inhibitor treatment alleviated priapism recurrences.
  • Although these preliminary findings suggest that continuous, long-term PDE5 inhibitor therapy may be useful as a preventative strategy for priapism, additional evaluation in the form of a controlled clinical trial is needed.
  • [MeSH-major] Carbolines / therapeutic use. Phosphodiesterase Inhibitors / therapeutic use. Piperazines / therapeutic use. Priapism / drug therapy
  • [MeSH-minor] 3',5'-Cyclic-GMP Phosphodiesterases. Adult. Anemia, Sickle Cell / complications. Cyclic Nucleotide Phosphodiesterases, Type 5. Erectile Dysfunction / etiology. Humans. Male. Nitric Oxide / metabolism. Penile Erection / drug effects. Penile Erection / physiology. Phosphoric Diester Hydrolases. Purines. Recurrence. Signal Transduction. Sildenafil Citrate. Sulfones. Tadalafil

  • Genetic Alliance. consumer health - Priapism.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. SILDENAFIL .
  • Hazardous Substances Data Bank. TADALAFIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698365.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbolines; 0 / Phosphodiesterase Inhibitors; 0 / Piperazines; 0 / Purines; 0 / Sulfones; 31C4KY9ESH / Nitric Oxide; 742SXX0ICT / Tadalafil; BW9B0ZE037 / Sildenafil Citrate; EC 3.1.4.- / Phosphoric Diester Hydrolases; EC 3.1.4.35 / 3',5'-Cyclic-GMP Phosphodiesterases; EC 3.1.4.35 / Cyclic Nucleotide Phosphodiesterases, Type 5; EC 3.1.4.35 / PDE5A protein, human
  •  go-up   go-down


13. Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CD: Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Am J Surg Pathol; 2009 Feb;33(2):218-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
  • Approximately 80% of advanced metastatic gastrointestinal stromal tumors (GISTs) respond to treatment with the tyrosine kinase inhibitor (TKI) imatinib mesylate.
  • However, the majority of patients suffer disease progression at a median of 2 years due to drug resistance.
  • Herein, we report 5 cases of progressing metastatic GIST with heterologous rhabdomyoblastic differentiation after TKI treatment.
  • There were 3 men and 2 women (ranging from 35 to 66 y of age).
  • Three tumors were localized at presentation (2 stomach and 1 small bowel) and 2 presented with metastases.
  • All localized primary tumors were high risk.
  • Two tumors showed spindle cell morphology and 3 were epithelioid, including 1 with marked pleomorphism.
  • After resection of the 3 localized primary tumors, intra-abdominal (2 patients) and liver (1 patient) metastases developed.
  • All patients were treated with imatinib and showed partial clinical responses (4 patient) or stable disease (1 patient).
  • At last follow-up (range: 20 to 87 mo), 2 patients died of disease, 2 were alive with metastatic disease resistant to TKIs, and 1 was alive without evidence of disease.
  • In all cases, rhabdomyoblastic differentiation was identified adjacent to areas with classic GIST morphology in at least 1 metastatic site; in 1 case, the primary tumor (after treatment with TKIs) showed heterologous differentiation.
  • No secondary mutations of the type associated with TKI resistance were identified in the rhabdomyoblastic areas.
  • This is the first report of rhabdomyoblastic differentiation occurring in GISTs that progressed on TKI therapy.
  • [MeSH-major] Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / pathology. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Benzamides. Cell Differentiation. DNA Mutational Analysis. Disease Progression. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Male. Middle Aged. Mutation. Protein-Tyrosine Kinases / antagonists & inhibitors. Stem Cell Factor / genetics

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18830121.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Stem Cell Factor; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


14. Chodorowski Z, Anand JS, Rutkowski P: [Neuroleptic malignant syndrome]. Przegl Lek; 2003;60(4):299-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroleptic malignant syndrome].
  • Neuroleptic malignant syndrome (NMS) is the most dangerous side effect of phenothiazines therapy.
  • In the period of time from 1995 to 2002 in the Intensive Toxicological Unit there were five patients, 3 men and 2 women, aged from 25 to 62 (average 44.2) years-old, admitted from the regional inpatients psychiatric units with the diagnosis of pneumonia and/or sepsis.
  • The neuroleptic drug was withdrawn and intensive supportive care with administration of bromocriptine (15-20 mg/24 h) was provided.
  • None one of the doctors told the patients about the possibility of NMS during phenothiazines therapy.
  • [MeSH-major] Bromocriptine / therapeutic use. Dopamine Agonists / therapeutic use. Neuroleptic Malignant Syndrome / complications. Respiratory Insufficiency / etiology. Respiratory Insufficiency / therapy

  • Genetic Alliance. consumer health - Neuroleptic malignant syndrome.
  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14569909.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Dopamine Agonists; 3A64E3G5ZO / Bromocriptine
  •  go-up   go-down


15. Mueller PS, Edwards WD, Gertz MA: Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med; 2000 Aug 15;109(3):181-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis.
  • RESULTS: Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis was found in 11 patients (8 men, 3 women).
  • The mean (+/-SD) age at the diagnosis of primary amyloidosis was 62 +/- 12 years.
  • Unstable coronary syndromes occurred in 7 patients and congestive heart failure in 8.
  • The diagnosis of obstructive intramural coronary amyloidosis with associated myocardial injury was established only at autopsy or after examination of the explanted heart after cardiac transplantation.
  • The mean time to death or cardiac transplantation after symptoms of cardiac ischemia developed was 18 +/- 20 months.
  • CONCLUSIONS: The diagnosis of ischemic heart disease resulting from obstructive intramural coronary amyloidosis is difficult to establish before death or cardiac transplantation.
  • Although the condition has a poor prognosis, its accurate recognition may have therapeutic implications, because some patients may benefit from treatment, including systemic chemotherapy or cardiac transplantation.
  • [MeSH-major] Amyloidosis / complications. Amyloidosis / diagnosis. Cardiomyopathies / complications. Cardiomyopathies / diagnosis. Myocardial Ischemia / etiology


16. Crawford LM, Sinha RN, Odell RM, Comi RJ: Efficacy of insulin pump therapy: mealtime delivery is the key factor. Endocr Pract; 2000 May-Jun;6(3):239-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of insulin pump therapy: mealtime delivery is the key factor.
  • OBJECTIVE: To investigate, in a clinical setting, the effect of implementation of continuous subcutaneous insulin infusion (CSII) on control of plasma glucose and to identify factors associated with improved glycemic control in patients with type 1 diabetes mellitus.
  • METHODS: Nineteen patients (16 women and 3 men) with type 1 diabetes were studied retrospectively.
  • The subjects underwent follow-up for a mean of 14 months after conversion to CSII therapy.
  • CONCLUSION: In a clinical setting, CSII therapy in patients with type 1 diabetes improves glycemic control and lowers the total daily basal insulin dose without affecting weight.
  • Improved glycemic control was associated with a shift in insulin therapy from a high percentage of intermediate-acting insulin to a greater percentage of insulin administered in a meal-associated bolus form.
  • This study emphasizes the importance of mealtime insulin adjustment for tight glycemic control in patients using CSII therapy.
  • [MeSH-major] Diabetes Mellitus, Type 1 / drug therapy. Hypoglycemic Agents / administration & dosage. Hypoglycemic Agents / therapeutic use. Insulin / administration & dosage. Insulin / therapeutic use. Insulin Infusion Systems
  • [MeSH-minor] Adult. Blood Glucose / metabolism. Body Mass Index. Body Weight / drug effects. Eating / physiology. Female. Hemoglobin A, Glycosylated / metabolism. Humans. Injections, Subcutaneous. Male. Middle Aged. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Endocr Pract. 2000 May-Jun;6(3):277-8 [11421546.001]
  • (PMID = 11421538.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Hemoglobin A, Glycosylated; 0 / Hypoglycemic Agents; 0 / Insulin
  •  go-up   go-down


17. Shiraishi Y, Katsuragi N, Kita H, Toishi M, Onda T: Experience with pulmonary resection for extensively drug-resistant tuberculosis. Interact Cardiovasc Thorac Surg; 2008 Dec;7(6):1075-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience with pulmonary resection for extensively drug-resistant tuberculosis.
  • Extensively drug-resistant tuberculosis is becoming a global threat.
  • We report our experience in using pulmonary resection for treating patients with this disease.
  • These patients were identified using the definition approved by the World Health Organization Global Task Force on extensively drug-resistant tuberculosis in October 2006.
  • Five (9%) patients (3 men and 2 women) aged 31-60 years met the definition.
  • Adjuvant resectional surgery was considered because the patients had localized disease.
  • All patients remained free from disease at the time of follow-up.
  • Pulmonary resection under cover of state-of-the-art chemotherapy is safe and effective for patients with localized extensively drug-resistant tuberculosis.
  • [MeSH-major] Antitubercular Agents / therapeutic use. Extensively Drug-Resistant Tuberculosis / surgery. Pneumonectomy
  • [MeSH-minor] Adult. Combined Modality Therapy. Drug Therapy, Combination. Female. Humans. Japan. Male. Middle Aged. Sputum / microbiology. Treatment Outcome

  • Genetic Alliance. consumer health - Tuberculosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812334.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


18. Sasaguri M, Noda K, Tashiro E, Notomo J, Tsuji E, Koga M, Arakawa K: The regression of left ventricular hypertrophy by imidapril and the reduction of serum procollagen type III amino-terminal peptide in hypertensive patients. Hypertens Res; 2000 Jul;23(4):317-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The regression of left ventricular hypertrophy by imidapril and the reduction of serum procollagen type III amino-terminal peptide in hypertensive patients.
  • Angiotensin-converting enzyme (ACE) inhibitors are known to be the most effective antihypertensive drugs for reducing left ventricular mass in hypertensives when compared to other classes of drugs.
  • In the present study, we evaluated the effects of imidapril, an ACE inhibitor, on serum procollagen type III amino-terminal peptide (PIIIP) levels as well as the left ventricular mass index (LVMI).
  • The subjects consisted of 15 patients (12 men and 3 women) in the outpatient clinic of our hospital who were diagnosed as essential hypertensives and who had not been treated with any antihypertensive medication prior to the study.
  • Left ventricular hypertrophy was observed in all of the patients, ie., LVMI >110 g/m2 in men and >106 g/m2 in women.
  • Blood pressure, LVMI, and serum PIIIP levels were measured before and after treatment with imidapril for 6 months.
  • Blood pressure significantly decreased in 12 patients, and the mean LVMI decreased significantly from 153.1 +/- 9.0 to 135.4 +/- 6.3 (p< 0.01) after treatment.
  • The changes in LVMI and PIIIP levels with treatment had significant correlation (r=0.639, p< 0.05).
  • The present study showed that imidapril reduces the left ventricular mass in hypertensives after 6 months of treatment, and that this may at least in part be due to a decrease in the collagen content of the hypertrophied heart, suggesting that serum PIIIP levels are a useful marker of the regression of left ventricular hypertrophy.
  • [MeSH-major] Angiotensin-Converting Enzyme Inhibitors / therapeutic use. Hypertension / blood. Hypertension / complications. Hypertrophy, Left Ventricular / drug therapy. Hypertrophy, Left Ventricular / etiology. Imidazoles / therapeutic use. Imidazolidines. Peptide Fragments / blood. Procollagen / blood
  • [MeSH-minor] Adult. Aged. Antihypertensive Agents / therapeutic use. Blood Pressure / drug effects. Drug Therapy, Combination. Echocardiography. Female. Humans. Male. Middle Aged. Trichlormethiazide / therapeutic use

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • Hazardous Substances Data Bank. TRICHLORMETHIAZIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10912767.001).
  • [ISSN] 0916-9636
  • [Journal-full-title] Hypertension research : official journal of the Japanese Society of Hypertension
  • [ISO-abbreviation] Hypertens. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Antihypertensive Agents; 0 / Imidazoles; 0 / Imidazolidines; 0 / Peptide Fragments; 0 / Procollagen; 0 / procollagen Type III-N-terminal peptide; BW7H1TJS22 / imidapril; Q58C92TUN0 / Trichlormethiazide
  •  go-up   go-down


19. Ciftci AO, Tanyel FC, Senocak ME, Büyükpamukçu N: Pheochromocytoma in children. J Pediatr Surg; 2001 Mar;36(3):447-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Information recorded for each patient included age, sex, past medical and family history, clinical characteristics, diagnostic methods, treatment, pathologic findings, and outcome.
  • Most of the tumors were right sided (n = 6) and bilateral (n = 6).
  • Sporadic cases of PHEO accounted for 14 patients (88%), whereas 2 children had von Hippel-Lindau (VHL) disease and multiple endocrine neoplasia type 2b (MEN2b).
  • The diagnosis of PHEO was made by laboratory and radiologic studies.
  • Preoperative medical therapy was done in all patients.
  • Laparotomy confirmed that 11 patients had localized, 4 patients had regional, and 1 patient had metastatic disease.
  • The localized tumors were excised totally by bilateral (n = 4) and unilateral (n = 6) adrenalectomy.
  • Surgical procedures performed for regional disease were total excision (n = 2), incisional biopsy (n = 1) and partial excision (n = 1).
  • Incisional biopsy could be taken only from a patient with metastatic disease at presentation.
  • Two patients with localized disease and 2 patients with regional disease had benign recurrences in right (n = 2) and left (n = 2) adrenal glands within 3 to 7 years after operation.
  • Total excision of the recurrent tumors was done in all patients.
  • Pathologic examination found apparently malignant features in 3 patients who presented with regional (n = 2) or metastatic (n = 1) disease and underwent incisional biopsy (n = 2) or partial excision (n = 1).
  • Pathologic features suggestive of malignancy were noted in 4 patients presenting with regional (n = 2) and localized disease (n = 2).
  • Adjuvant chemotherapy was commenced postoperatively in all patients with malignant and suggestive of malignant pathologic features.
  • One patient with VHL disease died of astrositoma 5 years after her recurrent PHEO was excised.
  • Of the 3 patients with malignant disease, 2 patients in whom only incisional biopsies were done had distant metastases and died of disease within 2 years.
  • Another patient with malignancy who had MEN2b was lost to follow-up.
  • CONCLUSIONS: Early diagnosis and total excision are the most important aspects of accurate treatment for childhood PHEO.
  • Pre- intra- and postoperative medical management is as important as the surgical procedure.
  • Our surgical treatment policy is mainly minimizing the risk of recurrence while preserving adequately functioning adrenal medullar tissue.
  • Incomplete excision and advanced-stage disease are the major determinants of poor outcome.
  • Because of the steadily increasing incidence of precancerous genetic syndromes related to adrenal glands and poor prognosis of advanced-stage PHEO, childhood cases of hypertensive disorders should receive a detailed and vigorous diagnostic evaluation and appropriate treatment as given to adults.
  • [MeSH-major] Adrenal Gland Neoplasms. Pheochromocytoma
  • [MeSH-minor] Adolescent. Child. Combined Modality Therapy. Female. Humans. Hypertension / etiology. Male. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Risk Factors. Treatment Outcome. Turkey


20. Munier A, Gras V, Andrejak M, Bernard N, Jean-Pastor MJ, Gautier S, Biour M, Massy Z: Zoledronic Acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother; 2005 Jul-Aug;39(7-8):1194-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We evaluated available cases with acute deterioration of renal function associated with zoledronic acid therapy drawn from the French Adverse Event Reporting System database until July 1, 2004.
  • RESULTS: We identified 4 men and 3 women between the ages of 52 and 70 years, with multiple myeloma or different types of metastatic cancer, who had experienced renal impairment during zoledronic acid therapy.
  • Four patients developed de novo acute renal failure, while the other 3 patients experienced acute deterioration of preexisting chronic renal failure.
  • Renal failure occurred after various durations of zoledronic acid therapy (1-120 days).
  • Our data confirm the previously reported risk factors for zoledronic acid-associated nephrotoxicity such as advanced cancer, multiple myeloma, preexisting renal failure, diabetes, hypertension, and concomitant use of nephrotoxic drugs.
  • CONCLUSIONS: These cases emphasize the need for regular monitoring of renal function during zoledronic acid treatment, with particular attention to patients with preexisting impaired renal function.
  • [MeSH-major] Bone Resorption / drug therapy. Diphosphonates / adverse effects. Imidazoles / adverse effects. Kidney Diseases / chemically induced. Kidney Diseases / epidemiology
  • [MeSH-minor] Acute Kidney Injury / chemically induced. Adverse Drug Reaction Reporting Systems. Aged. Databases, Factual. Female. France / epidemiology. Humans. Male. Middle Aged. Multiple Organ Failure / chemically induced. Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15956222.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


21. Clay CA, Perera S, Wagner JM, Miller ME, Nelson JB, Greenspan SL: Physical function in men with prostate cancer on androgen deprivation therapy. Phys Ther; 2007 Oct;87(10):1325-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physical function in men with prostate cancer on androgen deprivation therapy.
  • BACKGROUND AND PURPOSE: Androgen deprivation therapy (ADT) has become an increasingly standard intervention for both early and advanced stages of prostate cancer; however, decreased physical function and hypogonadism have been reported in men receiving ADT.
  • SUBJECTS AND METHODS: Physical function, walking speed, visuomotor performance, gonadal status, body composition, and Comorbidity Disease Index (CMDI) scores were assessed in a cohort of 100 participants that included:.
  • (1) men with prostate cancer who were not on ADT, (2) men with prostate cancer who were on short-term ADT (<6 months), (3) men with prostate cancer who were on long-term ADT (> or =6 months), and (4) control subjects who did not have prostate cancer.
  • Adjusted for covariates, men on long-term ADT walked 0.18 m/s slower than the control subjects.
  • Androgen deprivation therapy did not have a significant effect on visuomotor performance.
  • DISCUSSION AND CONCLUSION: The results suggest that ADT has a significant effect on walking speed and physical performance in men with prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17684084.001).
  • [ISSN] 0031-9023
  • [Journal-full-title] Physical therapy
  • [ISO-abbreviation] Phys Ther
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / P30 AG024827; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NIDDK NIH HHS / DK / K24 DK062895; United States / NCRR NIH HHS / RR / M01 RR000056
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


22. Gerstenfeld EP, Callans DJ, Sauer W, Jacobson J, Marchlinski FE: Reentrant and nonreentrant focal left atrial tachycardias occur after pulmonary vein isolation. Heart Rhythm; 2005 Nov;2(11):1195-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Both focal and macroreentrant atrial tachycardia (ATs) can occur after pulmonary vein (PV) isolation for treatment of atrial fibrillation (AF).
  • We report the response to pacing and pharmacologic maneuvers performed in patients with stable focal ATs after segmental PV isolation.
  • METHODS: Patients with persistent left AT after cessation of antiarrhythmic drug therapy presented for mapping and ablation.
  • Entrainment was performed from multiple right and left atrial sites.
  • RESULTS: Five patients (3 men and 2 women; age 65 +/- 10 years) had focal left AT that persisted in response to pacing maneuvers.
  • Tachycardias were entrained from multiple left atrial sites.
  • Recordings from the ablation catheter at the critical isthmus typically demonstrated mid-diastolic or long fractionated potentials.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253909.001).
  • [ISSN] 1547-5271
  • [Journal-full-title] Heart rhythm
  • [ISO-abbreviation] Heart Rhythm
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Szczech LA, Edwards LJ, Sanders LL, van der Horst C, Bartlett JA, Heald AE, Svetkey LP: Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol; 2002 May;57(5):336-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: While angiotensin-con-verting enzyme inhibitors and zidovudine may improve the course of the most common HIV-related renal disease, HIV-associated nephropathy (HIVAN), the effect of anti-retroviral combination therapy on this and other HIV-related renal diseases has not been assessed.
  • METHODS: This retrospective cohort study reviews the clinical course of 19 patients with a clinical or biopsy-proven diagnosis of HIVAN or other HIV-related renal diseases.
  • Groups progressing and not progressing to ESRD were compared using longitudinal analyses to assess the association between creatinine clearance and clinical and therapeutic factors.
  • Their modes of HIV infection were intravenous drug use (7), a history of men having sex with men (3) and heterosexual behavior (5).
  • Loss of creatinine clearance over time did not differ among genders, races, or patients with different modes of HIV infection.
  • Longitudinal analyses demonstrated an association between protease inhibitors and prednisone and a slower decline in creatinine clearance in multivariable models (p = 0.04 and 0.003, respectively).
  • [MeSH-major] AIDS-Associated Nephropathy / drug therapy. Glucocorticoids / therapeutic use. Prednisone / therapeutic use. Protease Inhibitors / therapeutic use. Reverse Transcriptase Inhibitors / therapeutic use
  • [MeSH-minor] Adult. Angiotensin-Converting Enzyme Inhibitors / therapeutic use. Creatinine / blood. Disease Progression. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Renal Manifestations of HIV .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12036191.001).
  • [ISSN] 0301-0430
  • [Journal-full-title] Clinical nephrology
  • [ISO-abbreviation] Clin. Nephrol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / 5-P30-AI28662; United States / NIAID NIH HHS / AI / AI 25868; United States / NIAID NIH HHS / AI / AI-94028; United States / NIDDK NIH HHS / DK / DK02724-01A1; United States / NICHD NIH HHS / HD / HD 37260; United States / NCRR NIH HHS / RR / RR-30-GCRC
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Glucocorticoids; 0 / Protease Inhibitors; 0 / Reverse Transcriptase Inhibitors; AYI8EX34EU / Creatinine; VB0R961HZT / Prednisone
  •  go-up   go-down


24. Porstmann AU, Marcus U, Pleyer U: [Primary diagnosis of syphilis by the ophthalmologist]. Klin Monbl Augenheilkd; 2002 May;219(5):349-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary diagnosis of syphilis by the ophthalmologist].
  • BACKGROUND: Throughout the developed world the reported incidence of sexually transmitted diseases is rising with previously unreported cases at rates of 40 - 70 %.
  • According to German sources, recent epidemiological data show a considerable increase of syphilis especially among homosexual men in larger cities.
  • None of the patients (3 men, 1 woman) belonged to a risk group, only one described systemic symptoms (urethritis and arthritis).
  • After systemic antibiotic therapy, the ocular diseases stabilized.
  • CONCLUSION: Diagnosis and therapy of syphilis is cost-effective.
  • Lues serology should be incorporated into routine lab diagnostics to aid in the detection of such cases.
  • [MeSH-major] Eye Diseases / diagnosis. Patient Care Team. Syphilis / diagnosis
  • [MeSH-minor] AIDS-Related Opportunistic Infections / diagnosis. AIDS-Related Opportunistic Infections / drug therapy. AIDS-Related Opportunistic Infections / epidemiology. AIDS-Related Opportunistic Infections / transmission. Adult. Chorioretinitis / diagnosis. Chorioretinitis / drug therapy. Chorioretinitis / epidemiology. Cross-Sectional Studies. Diagnosis, Differential. Female. Fluorescein Angiography. Germany. Humans. Male. Middle Aged. Ophthalmoscopy. Papilledema / diagnosis. Papilledema / drug therapy. Papilledema / epidemiology. Penicillins / therapeutic use. Syphilis Serodiagnosis. Urban Population / statistics & numerical data. Uveitis, Anterior / diagnosis. Uveitis, Anterior / drug therapy. Uveitis, Anterior / epidemiology


25. Tonstad S, Rosvold EO, Furu K, Skurtveit S: Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. J Intern Med; 2004 Apr;255(4):494-502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Demographic, medical, anthropometric and lifestyle data was obtained from 6233 men and 7521 women born in 1924/25, 1940/41, 1955 and 1960 that participated in the Oslo Health Study 2000-2001.
  • RESULTS: Of subjects with a heart attack, angina, stroke or diabetes 45% of men and 35% of women were taking a statin (P < 0.001).
  • Of subjects with cardiovascular disease (CVD) or diabetes taking statins 61% of men and 40% of women achieved total serum cholesterol levels < or =5 mmol L(-1).
  • The odds ratio for taking a statin was increased amongst subjects who also took antihypertensive drug(s) or acetylsalicylic acid, subjects with a family history of coronary heart disease (CHD) and women who had visited the general practitioner within the last year.
  • Amongst presumed healthy subjects use of statins increased from about 1% in women aged 40-45 years, to 7% at age 60 and to 12% at age 75 whilst the corresponding figures for men were 3%, 8% and 9%, respectively.
  • About 22% of men but <2% of women aged 60 who were not taking statins had a 10-year Framingham CHD risk score >20%.
  • CONCLUSION: People with CVD or diabetes remain undertreated with statins, women more so than men.
  • Use of other preventive drugs, the family history and recent contact with the general practitioner were the most important determinants of statin use in primary and secondary prevention.
  • Amongst healthy subjects aged 60 or 75 years women received statins disproportionately to their low CHD risk compared with men.
  • [MeSH-major] Anticholesteremic Agents / therapeutic use. Cardiovascular Diseases / drug therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Antihypertensive Agents / therapeutic use. Aspirin / therapeutic use. Body Mass Index. Cholesterol / blood. Coronary Disease / drug therapy. Coronary Disease / epidemiology. Coronary Disease / prevention & control. Family Health. Family Practice. Female. Humans. Male. Middle Aged. Norway / epidemiology. Patient Acceptance of Health Care

  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15049884.001).
  • [ISSN] 0954-6820
  • [Journal-full-title] Journal of internal medicine
  • [ISO-abbreviation] J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Antihypertensive Agents; 97C5T2UQ7J / Cholesterol; R16CO5Y76E / Aspirin
  •  go-up   go-down


26. Bourgeois H, Billiart I, Chabrun V, Chieze S, Lemerre D, Germain T, Ferrand V, Meurice JC, Daban A, Tourani JM: Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma. Am J Clin Oncol; 2004 Feb;27(1):89-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ifosfamide (I) has also been approved for NSCLC treatment.
  • In this study, one cycle of chemotherapy combined the following: ifosfamide: 3 g/m2 fixed dose (24-hour intravenous infusion) combined with mesna, day 1; gemcitabine: starting dose 1,000 mg/m2/d, escalating by 250 mg/m2 increments, days 1 and 15; cisplatin: starting dose 80 mg/m2, subsequently 100 mg/m2, day 15; in cohorts of at least 3 patients.
  • DLT was evaluated after the first chemotherapy cycle.
  • Thirty-three patients (30 men, 3 women) with stage III (14 patients)/IV (19 patients) NSCLC were treated at eight dose levels, receiving 109 cycles of chemotherapy.
  • Sixteen of 33 patients with measurable/evaluable disease had an objective response including two complete responses.
  • In conclusion, GIP chemotherapy is safe and appears to be active in patients with NSCLC.
  • A confirmatory phase II study is currently under way, before a phase III trial of GIP versus GP.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14758140.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


27. Al-toma A, Visser OJ, van Roessel HM, von Blomberg BM, Verbeek WH, Scholten PE, Ossenkoppele GJ, Huijgens PC, Mulder CJ: Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood; 2007 Mar 1;109(5):2243-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells.
  • Autologous hematopoietic stem cell transplantation (ASCT) is an increasingly accepted treatment for refractory autoimmune diseases.
  • Refractory celiac disease with aberrant T cells (RCD type II) is unresponsive to available therapies and carries a high risk of transition into enteropathy associated T-cell lymphoma (EATL).
  • This study reports on the feasibility, safety, and efficacy of ASCT in patients with RCD type II.
  • Thirteen patients with RCD type II were evaluated.
  • Seven patients (4 men, 3 women, mean age 61.5 years [range, 51-69 years]) underwent transplantation.
  • One patient died 8 months after transplantation from progressive neuroceliac disease.
  • These preliminary results showed that high-dose chemotherapy followed by ASCT seems feasible and safe and might result in long-term improvement of patients with RCD type II whose condition did not respond promptly to available drugs.
  • [MeSH-major] Celiac Disease / pathology. Celiac Disease / therapy. Hematopoietic Stem Cell Transplantation. T-Lymphocytes / pathology


28. Fukushima T, Yamamoto M, Oshiro S, Tsugu H, Hirakawa K, Soma G: Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas. Anticancer Res; 2003 Nov-Dec;23(6a):4473-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas.
  • BACKGROUND: This study assessed the safety, tolerance and preliminary efficacy of a combination chemotherapy regimen consisting of ranimustine (MCNU) and recombinant human mutant tumor necrosis factor-alpha (TNF-SAM2) for patients with newly diagnosed supratentorial malignant astrocytomas.
  • MATERIALS AND METHODS: The initial regimens were prescribed as adjuvant therapy in conjunction with radiotherapy following standard surgical treatment.
  • Ranimustine (MCNU) was administered intravenously at 100 mg/m2 on Day 1, i.e., at the onset of radiation therapy, and was followed by 80 x 10(4) U/m2 TNF-SAM2 intravenously from Day 3.
  • TNF-SAM2 was prescribed weekly for up to 5 injections during the postoperative period concurrent with radiation therapy.
  • The primary end-points were safety and tolerability and the secondary end-point was overall survival.
  • RESULTS: Twenty-six consecutive eligible patients, including 5 with anaplastic astrocytoma (3 men and 2 women) and 21 with glioblastoma (13 men and 8 women), were treated.
  • All of the 3 evaluable patients with anaplastic astrocytoma partially responded to treatment (PR), with a time to tumor progression (TTP) of 107 weeks and an estimated median survival time of 330 weeks.
  • Of the 15 evaluable patients with glioblastoma, 8 (53.3%) showed no change in response to the treatment (NC), while 7 (46.7%) had progressive disease (PD), with a time to tumor progression (TTP) of 36 weeks and an estimated median survival time of 69 weeks.
  • Although this regimen appeared to be safe, there was no improvement in response or survival time compared with a historical control of patients who received chemotherapy with MCNU alone in conjunction with radiotherapy for glioblastoma.
  • CONCLUSION: These results suggest that combined chemotherapy with mutant TNF-alpha (TNF-SAM2) in this patient population seems to be safe and tolerable and may benefit those with anaplastic astrocytoma.
  • These intriguing clinical observations warrant further evaluation to determine whether this approach can provide therapeutic benefits and improve survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / therapy. Brain Neoplasms / therapy. Nitrosourea Compounds / therapeutic use. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Immunotherapy. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14666736.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; 0 / TNF-SAM2; 0 / Tumor Necrosis Factor-alpha; RYH2T97J77 / ranimustine
  •  go-up   go-down


29. Zhang YJ, Chen MS, Liang HH, Xu L, Zhang YQ: [Clinicopathologic features and treatment outcomes of primary hepatic lymphoma: a report of four cases]. Ai Zheng; 2005 Mar;24(3):365-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic features and treatment outcomes of primary hepatic lymphoma: a report of four cases].
  • This article was to investigate clinicopathologic features and treatment of PHL.
  • RESULTS: Of the 4 patients, 3 were men, and 1 was woman, with a median age of 53 years old; 3 had single focus, and 1 had multi-foci.
  • All patents were positive for HBV antigen, 3 were misdiagnosed preoperatively, and 1 had no clear diagnosis before operation.
  • Two patients received resection, and 2 received biopsy; all patients received adjuvant chemotherapy postoperatively.
  • Resection followed by adjuvant chemotherapy with CHOP regiment seems to be the best option for PHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hepatectomy. Hodgkin Disease / therapy. Liver Neoplasms / therapy. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Diagnostic Errors. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Hepatitis Antigens / analysis. Humans. Male. Middle Aged. Prednisone / administration & dosage. Retrospective Studies. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757544.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Hepatitis Antigens; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


30. Clausen P, Mersebach H, Nielsen B, Feldt-Rasmussen B, Feldt-Rasmussen U: Hypothyroidism is associated with signs of endothelial dysfunction despite 1-year replacement therapy with levothyroxine. Clin Endocrinol (Oxf); 2009 Jun;70(6):932-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypothyroidism is associated with signs of endothelial dysfunction despite 1-year replacement therapy with levothyroxine.
  • DESIGN AND PATIENTS: Sixteen consecutive patients (13 women, 3 men, aged 46 +/- 11 years) with hypothyroidism were included and compared to 16 matched healthy controls (13 women, 3 men, aged 49 +/- 11 years).
  • [MeSH-major] Endothelium, Vascular / physiopathology. Hormone Replacement Therapy. Hypothyroidism / physiopathology. Thyroxine / therapeutic use
  • [MeSH-minor] Adult. Brachial Artery / drug effects. Brachial Artery / physiopathology. Case-Control Studies. Humans. Male. Middle Aged. Regional Blood Flow / drug effects

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18778398.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q51BO43MG4 / Thyroxine
  •  go-up   go-down


31. Stable angina--who needs revascularisation? Drug Ther Bull; 2007 Feb;45(2):12-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the UK, about 5% of men and 3% of women have, or have had, angina.
  • Also, estimates suggest that, each year, around 340,000 people present with the symptom for the first time.
  • Characterised by pain or discomfort in the chest, angina is usually caused by atherosclerotic coronary artery disease and so carries an increased risk of cardiovascular complications such as myocardial infarction and death from coronary heart disease (CHD).
  • To address these problems and the elevated cardiovascular risk, standard management includes lifestyle measures (e.g. physical activity without excessive exertion, stopping smoking, weight control); tackling other cardiovascular risk factors (e.g. raised blood pressure, diabetes mellitus); and medication to control angina (e.g. nitrates, beta-blockers, calcium antagonists) and to reduce overall cardiovascular risk (e.g. aspirin, statin therapy).
  • [MeSH-major] Angina Pectoris / therapy. Myocardial Revascularization

  • MedlinePlus Health Information. consumer health - Angina.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357474.001).
  • [ISSN] 0012-6543
  • [Journal-full-title] Drug and therapeutics bulletin
  • [ISO-abbreviation] Drug Ther Bull
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 37
  •  go-up   go-down


32. Dolfing JG, Wolffenbuttel BH, ten Hoor-Aukema NM, Schweitzer DH: Daily high doses of fluoxetine for weight loss and improvement in lifestyle before bariatric surgery. Obes Surg; 2005 Sep;15(8):1185-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endpoints of this study were body weight reductions, the number of individuals who decided for themselves to postpone surgery for at least 6 months, and side-effects of fluoxetine therapy.
  • RESULTS: 84 severely obese subjects consisting of 28 men (group 1) and 41 women (group 2) consented to take fluoxetine for its anorectic effects, whereas 12 men and 3 women who did not want to take fluoxetine served as the control group (group 3).
  • At 6 months, men had achieved a weight reduction (kg) of -8.3 (95% CI: -9.3 to -5.9), women of -13.3 (95% CI: -16.3 to -8.8), sex difference P<0.001, and controls of -1.6 (95% CI: -3.8 to -2.5) kg, group difference P<0.0001.
  • Only 2 men stopped fluoxetine because of annoying sexual side-effects.
  • At 6 months, 25 fluoxetine users (29.7%) and none of the controls consented to postpone the time of surgery for at least another 6 months.
  • CONCLUSION: Fluoxetine is effective to reduce weight in severely obese men and women who originally had requested to undergo bariatric surgery.
  • One-third of subjects who consented to take fluoxetine as an anorectic drug agreed to delay surgery for at least 6 months later than scheduled.
  • [MeSH-major] Appetite Depressants / therapeutic use. Fluoxetine / therapeutic use. Obesity, Morbid / drug therapy. Weight Loss / drug effects
  • [MeSH-minor] Adult. Bariatric Surgery. Female. Health Behavior. Humans. Life Style. Male. Middle Aged. Time Factors

  • MedlinePlus Health Information. consumer health - Weight Control.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197794.001).
  • [ISSN] 0960-8923
  • [Journal-full-title] Obesity surgery
  • [ISO-abbreviation] Obes Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Appetite Depressants; 01K63SUP8D / Fluoxetine
  •  go-up   go-down


33. Matsushita S, Naito T, Takebayashi M, Sato H, Shiota H: The prognosis of cases with massive subretinal hemorrhage after photodynamic therapy. J Med Invest; 2008 Aug;55(3-4):231-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognosis of cases with massive subretinal hemorrhage after photodynamic therapy.
  • PURPOSE: To investigate cases with massive subretinal hemorrhage after photodynamic therapy (PDT).
  • SUBJECTS AND METHODS: We studied four cases (3 men and 1 woman, mean 80.5 years old) with massive subretinal hemorrhage after PDT about type of disease, spot size, period to the onset of hemorrhage, visual acuity (VA) before and after PDT.
  • RESULTS: Four cases consisted of one with age-related macula degeneration (AMD) and 3 with polypoidal choroidal vasculopathy (PCV).
  • [MeSH-minor] Aged. Aged, 80 and over. Choroid / blood supply. Choroid Diseases / drug therapy. Female. Humans. Macular Degeneration / drug therapy. Male. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797136.001).
  • [ISSN] 1349-6867
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Prayson RA, Sebek BA: Parotid gland malignant melanomas. Arch Pathol Lab Med; 2000 Dec;124(12):1780-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malignant melanomas are relatively unusual tumors in the parotid gland.
  • RESULTS: Patients consisted of 9 men and 3 women ranging in age from 30 to 84 years (median, 66 years).
  • In 2 patients, a cutaneous melanoma and the parotid gland melanoma were diagnosed at the same time.
  • Four patients received adjuvant radiotherapy, and 3 patients received adjuvant chemotherapy.
  • Four of 11 patients had ipsilateral cervical lymph node metastasis at the time of parotid tumor resection, and 5 patients had involvement of intraparotid lymph nodes by metastatic melanoma.
  • Tumors ranged in size from 0.3 to 2.5 cm in greatest dimension.
  • Multiple parotid nodules were noted in 4 patients.
  • All tumors were characterized by a diffuse proliferation of cells with abundant eosinophilic cytoplasm and prominent nucleoli.
  • Four tumors demonstrated focal spindle cell regions.
  • Prognosis is generally poor, although rare patients may survive a long period of time following surgery.
  • [MeSH-major] Melanoma / pathology. Parotid Neoplasms / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11100057.001).
  • [ISSN] 0003-9985
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


35. Chamberlain MC, Raizer J: Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. J Neurooncol; 2009 Jun;93(2):229-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia.
  • OBJECTIVE: A case series of gliomas treated with alkylator-based chemotherapy who subsequently developed myelodysplastic syndrome (tMDS) or acute myelocytic leukemia (AML).
  • BACKGROUND: Alkylator-based chemotherapy is recognized to be leukemogenic; however, it is infrequently described as a delayed consequence of anti-glioma treatment.
  • METHODS: Seven patients (4 men; 3 women) ages 34-69 years (median 44), with gliomas (3 Grade 2; 4 Grade 3) were treated with surgery, all but one with involved-field radiotherapy and all with alkylator-based chemotherapy (temozolomide; 6 patients, nitrosoureas; 5 patients, both agents; 5 patients).
  • RESULTS: Exposure to alkylator-based chemotherapy ranged from 8 to 30 months (median 24).
  • The diagnosis of tMDS was determined by bone marrow biopsy in 7 patients.
  • Seven patients showed chromosomal abnormalities consistent with chemotherapy induced MDS.
  • Interval from last chemotherapy exposure to diagnosis of tMDS/AML ranged from 3 to 31 months (median 24 months).
  • CONCLUSIONS: Although rare, induction of tMDS/AML following extended use of alkylator-based chemotherapy may become more relevant with the evolving practice to treat gliomas for protracted periods.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Glioma / drug therapy. Myelodysplastic Syndromes / chemically induced
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Nitrosourea Compounds / therapeutic use. Reoperation / statistics & numerical data. Survival Analysis. Survivors. Time Factors

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2001 Feb;12 (2):259-66 [11300335.001]
  • [Cites] Neurology. 2001 Jul 24;57(2):340-2 [11468326.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] J Neurooncol. 2001 May;53(1):55-9 [11678432.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):315-8 [15735923.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] N Engl J Med. 1985 Aug 29;313(9):579 [3894973.001]
  • [Cites] Neurology. 2001 Jan 9;56(1):118-20 [11148250.001]
  • [Cites] Neurology. 2004 Jun 8;62(11):2113-5 [15184628.001]
  • [Cites] Oncology. 2002;63(1):38-41 [12187069.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):646-51 [12586801.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Neurooncol. 1998 Oct;40(1):39-46 [9874184.001]
  • [Cites] Neurol Med Chir (Tokyo). 2002 Apr;42(4):170-4 [12013670.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):280-3 [16728498.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3 Suppl 6):27-34 [10866347.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 19099199.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Nitrosourea Compounds; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


36. Vidal M, Wells S, Ryan A, Cagan R: ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res; 2005 May 1;65(9):3538-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.
  • Patients with hereditary medullary thyroid carcinoma (MTC) associated with multiple endocrine neoplasia (MEN) types 2A and 2B and familial MTC (FMTC) have mutations in the RET proto-oncogene.
  • The RET point mutations associated with MEN2A, MEN2B, or FMTC, or the chromosomal breakpoints and translocations associated with PTC, typically activate the RET receptor tyrosine kinase (RTK).
  • RET kinase inhibitors are likely to be beneficial for patients with hereditary MTC, where currently there is no effective chemotherapy or radiation therapy.
  • We have developed a Drosophila model for MEN2A and MEN2B diseases by targeting oncogenic forms of RET to the developing Drosophila eye.
  • Our results support the view that targeting chemical kinase inhibitors such as ZD6474 to tissues with oncogenic forms of RET is a useful treatment strategy for RET-dependent carcinomas.
  • [MeSH-major] Carcinoma, Papillary / drug therapy. Drosophila Proteins / antagonists & inhibitors. Multiple Endocrine Neoplasia Type 2a / drug therapy. Multiple Endocrine Neoplasia Type 2b / drug therapy. Piperidines / pharmacology. Quinazolines / pharmacology. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Animals. Disease Models, Animal. Drosophila. Eye Abnormalities / genetics. Protein Isoforms. Proto-Oncogene Proteins c-ret. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. raf Kinases / antagonists & inhibitors. raf Kinases / genetics. raf Kinases / metabolism. ras Proteins / antagonists & inhibitors. ras Proteins / genetics. ras Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • FlyBase. FlyBase .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867345.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA084309
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drosophila Proteins; 0 / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0 / Piperidines; 0 / Protein Isoforms; 0 / Quinazolines; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Ret oncogene protein, Drosophila; EC 2.7.11.1 / raf Kinases; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


37. Simpson ND, Simpson PW, Ahmed AM, Nguyen MH, Garcia G, Keeffe EB, Ahmed A: Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine. J Clin Gastroenterol; 2003 Jul;37(1):68-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine.
  • The results of lamivudine therapy in 4 patients with chemotherapy-induced hepatitis B virus (HBV) reactivation are reported.
  • Cancer chemotherapy-induced reactivation is a known complication in patients with chronic HBV infection or history of HBV infection with recovery.
  • The 4 patients treated with lamivudine included 1 woman with breast cancer and 3 men with non-Hodgkin lymphoma, ranging from 41 to 63 years of age.
  • All 4 patients were undergoing standard, multi-agent chemotherapy when they presented with HBV reactivation manifested by sudden onset of fatigue, jaundice, and HBV serology consistent with active HBV infection (detectable serum HBV DNA) in the absence of other known causes of acute hepatitis.
  • Lamivudine therapy (100 mg/d in 3 patients and 150 mg/d in 1 patient) was initiated from 1 to 18 days following the diagnosis of HBV reactivation.
  • All 4 patients showed rapid decrease in aminotransferase levels within 2 weeks after initiating lamivudine therapy.
  • The remaining 2 patients had suppression of HBV DNA to undetectable levels after 1 and 4 months of treatment and had biochemical and clinical improvement.
  • The 2 patients who died received lamivudine therapy for 8 days and for 3 weeks.
  • There have been no randomized clinical trials to study the role of lamivudine for prophylaxis or treatment of HBV reactivation associated with chemotherapy.
  • However, based on our limited experience, lamivudine may be efficacious in suppressing potentially fatal HBV reactivation secondary to chemotherapy in patients with chronic HBV infection or prior infection with recovery.
  • Patients who undergo chemotherapy should be screened for the presence of markers of chronic hepatitis B infection or previous HBV infection.
  • We recommend that patients with chronic HBV infection (positive HBV DNA and/or positive HBsAg) or history of HBV infection with recovery (positive hepatitis B core antibody with or without HBsAb) be considered for prophylactic lamivudine use to prevent chemotherapy-induced HBV reactivation.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Hepatitis B / prevention & control. Hepatitis B virus / growth & development. Lamivudine / therapeutic use. Reverse Transcriptase Inhibitors / therapeutic use. Virus Activation / drug effects
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12811213.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Reverse Transcriptase Inhibitors; 2T8Q726O95 / Lamivudine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


38. Günaydin I, Pereira PL, Daikeler T, Mohren M, Trübenbach J, Schick F, Kanz L, Kötter I: Magnetic resonance imaging guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study. J Rheumatol; 2000 Feb;27(2):424-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study.
  • OBJECTIVE: To evaluate magnetic resonance imaging (MRI) guided corticosteroid injections of inflamed sacroiliac (SI) joints in patients with spondyloarthropathy with therapy resistant sacroiliitis.
  • METHODS: We performed 16 injections in 9 patients on an outpatient basis (6 men, 3 women, mean age at onset 24.7 +/- 7.5 yrs).
  • CONCLUSION: MRI guided corticosteroid injection of SI joints appears to be an effective and safe procedure without exposure to radiation.
  • It is a useful therapeutic modality, especially in young patients with severe isolated sacroiliitis.
  • [MeSH-major] Adrenal Cortex Hormones / administration & dosage. Arthritis / drug therapy. Sacroiliac Joint / radiography
  • [MeSH-minor] Adolescent. Adult. Child. Drug Resistance. Female. Humans. Magnetic Resonance Imaging. Male. Pilot Projects

  • MedlinePlus Health Information. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10685809.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] CANADA
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


39. Souvatzidis P, Sbano P, Mandato F, Fimiani M, Castelli A: Malignant nodular hidradenoma of the skin: report of seven cases. J Eur Acad Dermatol Venereol; 2008 May;22(5):549-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The best method of treatment is still unclear: radical surgical excision is widely used, and selective lymph node dissection is also suggested.
  • The value of the adjuvant radiotherapy and chemotherapy has not been confirmed.
  • PATIENTS AND TREATMENT: Seven MNH patients (4 men, 3 women, age 60-87 years) were treated between 1991 and 2007 in the Dermatology Unit of San Donato Hospital of Arezzo and in the Section of Dermatology of University of Siena, Italy.
  • One patient underwent adjuvant radiotherapy, and three received chemotherapy.
  • Survival time was inversely proportional to the size of the tumour.
  • Histological parameters are paramount, but correct diagnosis also calls for attention to clinical presentation and any history of recurrence or recent enlargement of long-standing lesions.
  • In our experience, radiotherapy and chemotherapy do not seem to prolong survival.
  • [MeSH-major] Adenoma, Sweat Gland / diagnosis. Skin Neoplasms / diagnosis. Sweat Gland Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Fatal Outcome. Female. Humans. Male. Middle Aged. Prognosis. Skin / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for nodular hidradenoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410617.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 29
  •  go-up   go-down


40. Wendling D, Streit G, Toussirot E, Prati C: Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. Joint Bone Spine; 2008 Oct;75(5):540-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease.
  • METHODS: Retrospective review of the medical records of 300 patients who received TNFalpha antagonists to treat chronic inflammatory joint disease.
  • RESULTS: We identified 9 (9/300, 3%) patients who experienced herpes zoster, 6 women and 3 men, with rheumatoid arthritis (n=7) or ankylosing spondylitis (n=2).
  • The drug was infliximab in 4 patients, adalimumab in 2 patients, and etanercept in 3 patients, including 2 patients with a prior history of infliximab therapy (for 12 and 36 months, respectively).
  • Mean treatment duration at the occurrence of herpes zoster was 27 months (range, 6-42 months).
  • DISCUSSION: Glucocorticoid therapy (n=7) and methotrexate therapy (n=6) were the only risk factors identified in our study.
  • All 9 patients achieved a full recovery with antiviral treatment and interruption of the TNFalpha antagonist.
  • One patient experienced a recurrence after resuming TNFalpha antagonist therapy.
  • The role for concomitant treatments (glucocorticoids and methotrexate) should be taken into account.
  • [MeSH-major] Antirheumatic Agents / adverse effects. Arthritis, Rheumatoid / drug therapy. Herpes Zoster / etiology. Spondylitis, Ankylosing / drug therapy. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Acyclovir / analogs & derivatives. Acyclovir / therapeutic use. Adalimumab. Adult. Aged, 80 and over. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Antiviral Agents / therapeutic use. Drug Therapy, Combination. Etanercept. Female. Glucocorticoids / adverse effects. Humans. Immunoglobulin G / adverse effects. Immunosuppressive Agents / adverse effects. Infliximab. Male. Methotrexate / adverse effects. Middle Aged. Receptors, Tumor Necrosis Factor. Retrospective Studies. Risk Factors. Valine / analogs & derivatives. Valine / therapeutic use

  • MedlinePlus Health Information. consumer health - Ankylosing Spondylitis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • MedlinePlus Health Information. consumer health - Shingles.
  • Hazardous Substances Data Bank. Valacyclovir .
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. Etanercept .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. ACYCLOVIR .
  • Hazardous Substances Data Bank. L-Valine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18674945.001).
  • [ISSN] 1778-7254
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antirheumatic Agents; 0 / Antiviral Agents; 0 / Glucocorticoids; 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab; FYS6T7F842 / Adalimumab; HG18B9YRS7 / Valine; MZ1IW7Q79D / valacyclovir; OP401G7OJC / Etanercept; X4HES1O11F / Acyclovir; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


41. Brügemann J, van der Bij W, Verschuuren EA, Klungel AA, van der Horst IC, Erasmus ME, Kerstjens HA, van Veldhuisen DJ, Zijlstra F: [Experiences of combined heart-lung transplantations in the University Medical Center Groningen]. Ned Tijdschr Geneeskd; 2009;153:B98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The study group consisted of 14 patients (3 men and 11 women) with a mean age of 41 years.
  • Indications for heart-lung transplantation were: congenital heart disease complicated by pulmonary hypertension (6 patients), idiopathic pulmonary hypertension with severe right ventricle failure (4 patients), lung fibrosis with severe right ventricle failure (1 patient), cystic fibrosis with systolic left ventricle failure (1 patient), pulmonary hypertension after thoracic radiation and chemotherapy (1 patient) and re-transplantation after lung-transplant failure (1 patient).
  • The mean waiting time prior to operation was approximately 1.5 years.
  • At the end of the study 6 of the 14 patients (43%) were alive, with a mean survival period of 58 months (range: 6-132).
  • The waiting time in this study was long and the post-transplantation mortality was high.
  • [MeSH-minor] Adult. Cause of Death. Cystic Fibrosis / complications. Cystic Fibrosis / therapy. Female. Heart Diseases / complications. Heart Diseases / therapy. Humans. Hypertension, Pulmonary / complications. Hypertension, Pulmonary / therapy. Immunosuppressive Agents / administration & dosage. Male. Middle Aged. Netherlands. Retrospective Studies. Survival Rate. Waiting Lists. Young Adult

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19785831.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


42. Susekov AV, Solov'eva EIu, Zubareva MIu, Kukharchuk VV: [Simvastatin (40 mg/day) in patients with hereditary hypercholesterolemia: effect on high density lipoprotein cholesterol]. Kardiologiia; 2002;42(12):38-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: Simvastatin (40 mg/day) was given for 3 months to 15 patients (3 men, 12 women, mean age 56-/+10.3 years) with hereditary type II hypercholesterolemia after washout from lipid lowering therapy.
  • Blood lipids, activity of liver enzymes and creatine kinase were determined after 1 and 3 months of therapy with simvastatin.
  • In 1 patient the drug was stopped because of pain in the liver and nausea.
  • In patients with initially low HDL CH levels of total and low density lipoprotein (LDL) CH significantly decreased by 29.6 and 36.8%, respectively, after 3 months, while level of HDL CH increased by 20% after 1 month of therapy.
  • [MeSH-major] Anticholesteremic Agents / pharmacology. Anticholesteremic Agents / therapeutic use. Cholesterol, HDL / metabolism. Hypercholesterolemia / drug therapy. Hypercholesterolemia / genetics. Simvastatin / pharmacology. Simvastatin / therapeutic use
  • [MeSH-minor] Drug Administration Schedule. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hypercholesterolemia.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • Hazardous Substances Data Bank. SIMVASTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12494016.001).
  • [ISSN] 0022-9040
  • [Journal-full-title] Kardiologiia
  • [ISO-abbreviation] Kardiologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Cholesterol, HDL; AGG2FN16EV / Simvastatin
  •  go-up   go-down


43. Krasagakis K, Samonis G, Maniatakis P, Georgala S, Tosca A: Bullous erysipelas: clinical presentation, staphylococcal involvement and methicillin resistance. Dermatology; 2006;212(1):31-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bullous erysipelas represents a severe form of the disease.
  • OBJECTIVE: To evaluate the clinical and microbiological characteristics and treatment of bullous erysipelas.
  • METHODS: Patients with a diagnosis of bullous erysipelas who were treated at the Department of Dermatology, University Hospital of Heraklion, Crete, Greece, between the years 1996 and 2001 were retrospectively studied.
  • RESULTS: Fourteen patients (11 women, 3 men) with bullous erysipelas were evaluated.
  • The median duration of disease before hospital admission was 4 days.
  • The initial empirical antibiotic treatment included intravenous beta-lactams and was modified according to the sensitivities of the isolated strains.
  • The frequency of MRSA isolation suggests that beta-lactam antibiotics may not be sufficient for the treatment of bullous erysipelas anymore, at least in areas with a high incidence of MRSA strains.
  • [MeSH-minor] Adult. Aged. Anti-Bacterial Agents / therapeutic use. Cefuroxime / therapeutic use. Cloxacillin / therapeutic use. Drug Therapy, Combination. Female. Humans. Male. Methicillin / pharmacology. Methicillin / therapeutic use. Methicillin Resistance. Middle Aged. Netilmicin / therapeutic use. Penicillins / therapeutic use. Staphylococcus / drug effects. Staphylococcus / isolation & purification. Treatment Outcome. Vancomycin / therapeutic use

  • Genetic Alliance. consumer health - Erysipelas.
  • Hazardous Substances Data Bank. Vancomycin .
  • Hazardous Substances Data Bank. NETILMICIN .
  • Hazardous Substances Data Bank. METHICILLIN .
  • Hazardous Substances Data Bank. CLOXACILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • [CommentIn] Dermatology. 2006;212(1):1-3 [16319465.001]
  • [CommentIn] Dermatology. 2007;214(2):191-2; author reply 192-3 [17341875.001]
  • (PMID = 16319471.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Penicillins; 4O5J85GJJB / Netilmicin; 6Q205EH1VU / Vancomycin; O1R9FJ93ED / Cefuroxime; O6X5QGC2VB / Cloxacillin; Q91FH1328A / Methicillin
  •  go-up   go-down


44. Grant JE, Kim SW: An open-label study of naltrexone in the treatment of kleptomania. J Clin Psychiatry; 2002 Apr;63(4):349-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label study of naltrexone in the treatment of kleptomania.
  • BACKGROUND: The present study was designed to test the short-term efficacy and safety of naltrexone in the treatment of kleptomania.
  • METHOD: 10 subjects (7 women, 3 men) who fulfilled DSM-IV criteria for kleptomania and were free from other Axis I diagnoses by the Structured Clinical Interview for DSM-IV screening participated in a 12-week naltrexone open-label trial.
  • Subjects showed significant improvement (p < .005) over the 11-week treatment period in all measures compared with measures taken at baseline.
  • Seven subjects (70.0%) were very much improved and 2 (20.0%) were much improved at study end.
  • Men responded to naltrexone as well as women.
  • Nausea was common during the first week of treatment.
  • Five subjects (50.0%) reported previous trials of medication and cognitive-behavioral therapy without any effect on kleptomania symptoms.
  • CONCLUSION: The present findings provide evidence that naltrexone may be effective in the treatment of kleptomania.
  • [MeSH-major] Disruptive, Impulse Control, and Conduct Disorders / drug therapy. Naltrexone / therapeutic use. Narcotic Antagonists / therapeutic use
  • [MeSH-minor] Adult. Ambulatory Care. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Placebos. Psychiatric Status Rating Scales / statistics & numerical data. Reproducibility of Results. Severity of Illness Index. Sex Factors. Single-Blind Method. Treatment Outcome

  • Hazardous Substances Data Bank. NALTREXONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12000210.001).
  • [ISSN] 0160-6689
  • [Journal-full-title] The Journal of clinical psychiatry
  • [ISO-abbreviation] J Clin Psychiatry
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Narcotic Antagonists; 0 / Placebos; 5S6W795CQM / Naltrexone
  •  go-up   go-down


45. Soroush-Yari A, Burstein S, Hoo GW, Santiago SM: Pulmonary hypertension in men with thyrotoxicosis. Respiration; 2005 Jan-Feb;72(1):90-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary hypertension in men with thyrotoxicosis.
  • In patients with thyrotoxicosis and pulmonary hypertension, treatment of thyrotoxicosis alone is associated with improvement in pulmonary hypertension.
  • Previous reports have consisted of mostly female patients, but we report 3 men.
  • When all cases are considered, the typical patient is female (10/14 = 71%), middle-aged (48 years), with mean pulmonary artery systolic pressures improving from 56 to 32 mm Hg with treatment.
  • The response to treatment (medical or surgical) of thyrotoxicosis supports the hypothesis that hyperthyroidism is either a cause of pulmonary hypertension, or a factor that may unmask pulmonary hypertension.
  • Recognition is important since treatment and response are very different compared to other patients with pulmonary hypertension.
  • This association may not be readily considered in men, since most reports have been of women.
  • [MeSH-minor] Adult. Aged. Antihypertensive Agents / therapeutic use. Antithyroid Agents / therapeutic use. Disease Progression. Drug Therapy, Combination. Echocardiography. Humans. Iodine Radioisotopes / therapeutic use. Male. Middle Aged. Propranolol / therapeutic use. Propylthiouracil / therapeutic use. Pulmonary Wedge Pressure / physiology. Thyrotropin / blood. Thyroxine / blood

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. PROPYL THIOURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15753642.001).
  • [ISSN] 0025-7931
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Antithyroid Agents; 0 / Iodine Radioisotopes; 721M9407IY / Propylthiouracil; 9002-71-5 / Thyrotropin; 9Y8NXQ24VQ / Propranolol; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


46. Shammas NW, Harris ML, McKinney D, Hauber WJ: Digoxin withdrawal in patients with dilated cardiomyopathy following normalization of ejection fraction with beta blockers. Clin Cardiol; 2001 Dec;24(12):786-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In 8 consecutive patients with IDCM (5 men, 3 women) who had normalization of LVEF following beta-blocker treatment, digoxin was withdrawn as part of an office protocol. and LVEF was followed.
  • CONCLUSION: These data provide potential evidence that digoxin withdrawal can result in a small but significant reduction in LVEF in patients with IDCM who had normalization of LVEF after treatment with beta blockers.
  • Mean LVEF, however, remained within normal (> 50%) on beta-blocker therapy and without digitalis.
  • [MeSH-major] Angiotensin-Converting Enzyme Inhibitors / pharmacology. Cardiomyopathy, Dilated / drug therapy. Digoxin / pharmacology. Ventricular Function, Left / drug effects
  • [MeSH-minor] Adrenergic beta-Antagonists / therapeutic use. Aged. Female. Humans. Male. Middle Aged. Stroke Volume / drug effects

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • Genetic Alliance. consumer health - Dilated Cardiomyopathy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DIGOXIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11768743.001).
  • [ISSN] 0160-9289
  • [Journal-full-title] Clinical cardiology
  • [ISO-abbreviation] Clin Cardiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors; 73K4184T59 / Digoxin
  •  go-up   go-down


47. Park YH, Kim BS, Ryoo BY, Yang SH: A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer; 2006 Apr 10;94(7):959-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer.
  • Twenty evaluable patients (17 men, 3 women) with a median age of 64 years (range 38-75) were enrolled.
  • The most common haematological adverse event was anaemia (65% of patients) and the most common nonhaematological toxicities were vomiting (65%), neuropathy (60%), diarrhoea (30%), and hand-foot syndrome (20%).
  • In conclusion, XELOX is apparently as effective as triplet combinations and is well tolerated as first-line therapy for advanced gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Female. Fluorouracil / analogs & derivatives. Humans. Infusions, Intravenous. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Chronic Dis. 1961 Apr;13:346-53 [13704181.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2282-92 [11304782.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1759-66 [11919232.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):566-75 [12056707.001]
  • [Cites] Ann Oncol. 2002 Dec;13(12):1893-8 [12453857.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4543-8 [12454110.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1307-12 [12663719.001]
  • [Cites] Oncology. 2003;64(3):232-6 [12697963.001]
  • [Cites] Ann Oncol. 2003 Sep;14(9):1378-82 [12954576.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 15):54-61 [14523796.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1735-43 [14630678.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):658-63 [14966088.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1190-7 [15026800.001]
  • [Cites] Br J Cancer. 2004 Apr 5;90(7):1329-33 [15054450.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2084-91 [15169795.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):453-8 [15226770.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1344-7 [15319239.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3813-8 [8508349.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):494-501 [15659494.001]
  • [Cites] Int J Colorectal Dis. 2005 Mar;20(2):89-93 [15688098.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1644-9 [15856038.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]
  • [Cites] Br J Cancer. 2005 Jul 25;93(2):190-4 [16012522.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1320-5 [15919687.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):269-72 [10390007.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(4):291-7 [10755317.001]
  • (PMID = 16552439.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2361232
  •  go-up   go-down


48. Okuda K, Hirose T, Ishida H, Kusumoto S, Sugiyama T, Ando K, Shirai T, Ohnishi T, Horichi N, Ohmori T, Adachi M: Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol; 2008 Apr;61(5):829-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: From May 2004 through June 2005, 21 patients (18 men and 3 women; median age, 63 years; age range, 53-75 years) were enrolled.
  • Although two patients had grade 3 or 4 pulmonary toxicity due to Pneumocystis carinii pneumonia, these patients recovered after receiving trimetoprim-sulfamethoxazole, steroid therapy, and supplemental oxygen.
  • There were no treatment-related deaths.
  • CONCLUSION: This combination chemotherapy is active and well tolerated and warrants phase II study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Dose-Response Relationship, Drug. Drug-Induced Liver Injury. Female. Fever / chemically induced. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neutropenia / chemically induced. Organoplatinum Compounds / administration & dosage. Paclitaxel / administration & dosage. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17589845.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


49. Koziński M, Bielis L, Wiśniewska-Szmyt J, Sukiennik A, Grabczewska Z, Swiatkiewicz I, Ziołkowski M, Rość D, Kubica J: Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report. Cardiol J; 2008;15(6):530-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report.
  • Similarly, enhanced morning platelet aggregation has been observed in healthy individuals and in subjects with coronary artery disease without adequate antiplatelet treatment.
  • The purpose of the study was to assess circadian variation in platelet aggregation in patients with first ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary interventions (pPCI) and dual antiplatelet therapy.
  • METHODS: Fifteen consecutive patients (12 men and 3 women) were prospectively recruited into the study.
  • CONCLUSIONS: Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first STEMI undergoing pPCI.
  • The clinical significance of this finding remains to be demonstrated.
  • [MeSH-major] Circadian Rhythm / physiology. Electrocardiography. Myocardial Infarction / drug therapy. Platelet Aggregation / drug effects. Platelet Aggregation Inhibitors / therapeutic use
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Anticoagulants / administration & dosage. Anticoagulants / therapeutic use. Dose-Response Relationship, Drug. Drug Administration Routes. Drug Therapy, Combination. Female. Follow-Up Studies. Heparin / administration & dosage. Heparin / therapeutic use. Humans. Immunoglobulin Fab Fragments / administration & dosage. Immunoglobulin Fab Fragments / therapeutic use. Male. Middle Aged. Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors. Ticlopidine / administration & dosage. Ticlopidine / analogs & derivatives. Ticlopidine / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • Hazardous Substances Data Bank. CLOPIDOGREL .
  • Hazardous Substances Data Bank. Abciximab .
  • Hazardous Substances Data Bank. HEPARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19039757.001).
  • [ISSN] 1897-5593
  • [Journal-full-title] Cardiology journal
  • [ISO-abbreviation] Cardiol J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Anticoagulants; 0 / Immunoglobulin Fab Fragments; 0 / Platelet Aggregation Inhibitors; 0 / Platelet Glycoprotein GPIIb-IIIa Complex; 9005-49-6 / Heparin; A74586SNO7 / clopidogrel; OM90ZUW7M1 / Ticlopidine; X85G7936GV / abciximab
  •  go-up   go-down


50. Fiala KA, Casa DJ, Roti MW: Rehydration with a caffeinated beverage during the nonexercise periods of 3 consecutive days of 2-a-day practices. Int J Sport Nutr Exerc Metab; 2004 Aug;14(4):419-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten (7 women, 3 men) partially heat- acclimated athletes (age 24 +/-1y, body fat 19.2 +/- 2 %, weight 68.4 +/- 4.0 kg, height 170 +/- 3 cm) completed 3 successive days of 2-a-day practices (2 h/practice, 4 h/d) in mild heat (WBGT = 23 C).
  • A significant difference was found for urine color for the post-AM time point, F = 5.526, P = 0.031.
  • [MeSH-major] Caffeine / administration & dosage. Carbonated Beverages. Central Nervous System Stimulants / administration & dosage. Dehydration / prevention & control. Exercise / physiology. Fluid Therapy / methods
  • [MeSH-minor] Adult. Analysis of Variance. Cross-Over Studies. Double-Blind Method. Female. Humans. Male. Psychomotor Performance / drug effects. Specific Gravity. Time Factors. Urinalysis

  • MedlinePlus Health Information. consumer health - Caffeine.
  • MedlinePlus Health Information. consumer health - Dehydration.
  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15467100.001).
  • [ISSN] 1526-484X
  • [Journal-full-title] International journal of sport nutrition and exercise metabolism
  • [ISO-abbreviation] Int J Sport Nutr Exerc Metab
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 3G6A5W338E / Caffeine
  •  go-up   go-down


51. Lu CH, Chang WN: Adults with meningitis caused by oxacillin-resistant Staphylococcus aureus. Clin Infect Dis; 2000 Sep;31(3):723-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 11 patients were 8 men and 3 women, aged 17-78 years.
  • Infection with S. aureus only was found in 8 patients, and mixed infection was found in the other 3.
  • The diagnosis of adult ORSA meningitis can be confirmed only with a positive culture of cerebrospinal fluid, and the choice of initial empirical antibiotics must be guided by the accumulated data concerning the relative frequency of the implicated pathogens found at each institution.
  • Despite the high rate of mortality associated with ORSA meningitis, intravenous vancomycin therapy seems to be one of the best choices for management of this condition in adults.
  • [MeSH-minor] Adolescent. Adult. Aged. Ampicillin / pharmacology. Drug Resistance, Microbial. Drug Resistance, Multiple. Female. Hospitals / statistics & numerical data. Humans. Male. Microbial Sensitivity Tests. Middle Aged. Penicillin G / pharmacology. Time Factors. Vancomycin / pharmacology

  • MedlinePlus Health Information. consumer health - Meningitis.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • Hazardous Substances Data Bank. Vancomycin .
  • Hazardous Substances Data Bank. PENICILLIN G .
  • Hazardous Substances Data Bank. AMPICILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11017822.001).
  • [ISSN] 1058-4838
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 6Q205EH1VU / Vancomycin; 7C782967RD / Ampicillin; Q42T66VG0C / Penicillin G; UH95VD7V76 / Oxacillin
  •  go-up   go-down


52. Bellantone R, Boscherini M, Lombardi CP, Alesina PF: Medullary thyroid carcinoma: surgical management of primary tumor and locoregional recurrence. Rays; 2000 Apr-Jun;25(2):267-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medullary thyroid carcinoma is a rare neoplasm (3-9% of all thyroid tumors).
  • Surgery represents the only strategy for potential cure of the disease in whichi.
  • Medullary thyroid carcinoma in which locoregional lymph node metastases are an early occurrence cannot be treated with radioiodine therapy and it is minimally sensitive to chemotherapy and external beam radiation therapy.
  • Therefore total thyroidectomy with lymphadenectomy is the treatment of choice.
  • Ipsilateral laterocervical lymphadenectomy is essential for neoplasms > 10 mm in size in case of central and ipsilateral laterocervical lymph node involvement; bilateral laterocervical lymphadenectomy should be performed in all patients with bilateral lymphadenopathy and in some cases of MEN 2B.
  • In recurrence, reoperation is the single possible treatment with satisfactory results in terms of prognosis.
  • [MeSH-major] Carcinoma / surgery. Thyroid Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11370544.001).
  • [ISSN] 0390-7740
  • [Journal-full-title] Rays
  • [ISO-abbreviation] Rays
  • [Language] eng; ita
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 25
  •  go-up   go-down


53. Pappert EJ, Goetz CG, Louis ED, Blasucci L, Leurgans S: Objective assessments of longitudinal outcome in Gilles de la Tourette's syndrome. Neurology; 2003 Oct 14;61(7):936-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Objective assessments of longitudinal outcome in Gilles de la Tourette's syndrome.
  • OBJECTIVE: To define the long-term outcome in Gilles de la Tourette syndrome (GTS) using objective rating measures.
  • METHODS: The authors reviewed all videotapes in their database (1978 through 1991) of children with GTS (ages 8 to 14) who were seen in their tertiary care movement disorder center and underwent a standardized 5-minute filming protocol (n = 56).
  • Through multiple contact methods, they successfully located 36 of these patients, who are now adults (age >20 years), and recruited 31 (28 men and 3 women) to volunteer for a second videotape and in-person assessment.
  • Using standardized GTS videotape rating scale and Wilcoxon signed-rank tests with Bonferroni correction for multiple comparisons, the authors compared the two videotapes for each tic domain as well as the composite tic disability score.
  • The improvements in tic disability did not relate to medication use, as only 13% of adults received medications for tics, compared with 81% of children.
  • CONCLUSIONS: In GTS syndrome, tics objectively improve over time but most adults have persistent tics.
  • [MeSH-major] Tourette Syndrome / diagnosis. Tourette Syndrome / physiopathology
  • [MeSH-minor] Adolescent. Adult. Antipsychotic Agents / therapeutic use. Child. Chronic Disease. Disability Evaluation. Disease Progression. Female. Health Status. Humans. Interpersonal Relations. Learning Disorders / etiology. Longitudinal Studies. Male. Remission, Spontaneous. Tics / diagnosis. Tics / drug therapy. Tics / etiology. Video Recording

  • MedlinePlus Health Information. consumer health - Tourette Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14557563.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS01863
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


54. Kaşifoğlu T, Yalçin AU: The effects of thiazide and thiazide-potassium sparing diuretics on fibrinolytic system parameters. Anadolu Kardiyol Derg; 2006 Jun;6(2):143-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twenty-eight hypertensive patients (20 men, 8 women) visiting our hypertension unit were included in the study.
  • The patients in the 1st group (7 men, 2 women, mean age 48.55+/-6.14 years) were given 50 mg hydrochlorothiazide (HCT), whereas patients in the 2nd group (7 men, 2 women, mean age 48+/-6.3 years) received a combination of 50 mg HCT and 5 mg amyloride and the 3rd group (7 men, 3 women, mean age 48.2+/-7.25 years) took 50 mg HCT and 50 mg spironolactone for a period of 2 weeks.
  • The plasminogen activator inhibitor (PAI)-I, tissue plasminogen activator (t-PA) and PAI-I/t-PA ratio were assessed before and after treatment.
  • RESULTS: Treatment with HCT-spironolactone caused an increase in PAI-I (p<0.001) and t-PA ( p<0.001), while no changes were observed in PAI-I/t-PA (P>0.05).
  • Hydrochlorothiazide, HCT-amyloride and HCT-spironolactone treatments caused a significant decrease in the baseline blood pressure values (p<0.001).
  • Uric acid levels had increased after treatment with HCT (p<0.01) and HCT-amyloride (p<0.001), but no changes were observed in individuals receiving HCT-spironolactone (p>0.05).
  • [MeSH-major] Antihypertensive Agents / therapeutic use. Diuretics / therapeutic use. Hypertension / drug therapy
  • [MeSH-minor] Amiloride / administration & dosage. Amiloride / therapeutic use. Drug Therapy, Combination. Female. Fibrinolysis / drug effects. Humans. Hydrochlorothiazide / administration & dosage. Hydrochlorothiazide / therapeutic use. Male. Middle Aged. Mineralocorticoid Receptor Antagonists / administration & dosage. Mineralocorticoid Receptor Antagonists / therapeutic use. Plasminogen Activator Inhibitor 1 / blood. Spironolactone / administration & dosage. Spironolactone / therapeutic use. Tissue Plasminogen Activator / blood. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • Hazardous Substances Data Bank. SPIRONOLACTONE .
  • Hazardous Substances Data Bank. HYDROCHLOROTHIAZIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16766279.001).
  • [ISSN] 1302-8723
  • [Journal-full-title] Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
  • [ISO-abbreviation] Anadolu Kardiyol Derg
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Diuretics; 0 / Mineralocorticoid Receptor Antagonists; 0 / Plasminogen Activator Inhibitor 1; 0J48LPH2TH / Hydrochlorothiazide; 27O7W4T232 / Spironolactone; 7DZO8EB0Z3 / Amiloride; EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down


55. Bergman S, Accortt N, Turner A, Glaze J: Hepatitis C infection is acquired pre-ESRD. Am J Kidney Dis; 2005 Apr;45(4):684-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hepatitis C is more prevalent in patients with end-stage renal disease (ESRD) than in the general population.
  • Testing for anti-HCV was performed at the initiation of dialysis therapy and then yearly from August 1998 through August 2004.
  • Anti-HCV occurred in black men 3 times more than in black women (odds ratio, 3.3; 95% confidence interval, 2.2 to 5.0).
  • Age, race, sex, and history of drug abuse were predictors of anti-HCV positivity.
  • New patients are major contributors to the prevalence of anti-HCV in patients with ESRD, particularly those who are younger, male, black, or have a history of drug use.
  • Measuring anti-HCV levels in patients with chronic kidney disease may help identify those at risk for additional disorders.
  • [MeSH-minor] Adult. African Americans / statistics & numerical data. Aged. Alabama / epidemiology. Community-Acquired Infections / epidemiology. Comorbidity. Cross Infection / epidemiology. Diabetes Complications / epidemiology. European Continental Ancestry Group / statistics & numerical data. Female. Follow-Up Studies. HIV Infections / epidemiology. Hepatitis B / epidemiology. Hepatitis C Antibodies / blood. Humans. Male. Middle Aged. Renal Dialysis / adverse effects. Risk Factors. Seroepidemiologic Studies. Substance-Related Disorders / epidemiology. Time Factors

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806471.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis C Antibodies
  •  go-up   go-down


56. Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H, Suda T, Chida K: Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung; 2009 May-Jun;187(3):201-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis.
  • Interstitial lung disease (ILD) associated with polymyositis/dermatomyositis (ILD-PM/DM), including amyopathic dermatomyositis (ADM), is recognized as an important condition because it frequently causes death, despite intensive therapy with high-dose corticosteroid and immunosuppressive agents, such as cyclosporine A and cyclophosphamide.
  • Intravenous immunoglobulin therapy (IVIG) has shown efficacy for myopathy associated with PM/DM, but its usefulness for ILD-PM/DM is unclear.
  • A review was made of medical charts of five patients (2 men and 3 women) who were treated with IVIG for refractory ILD-PM/DM resistant to high-dose corticosteroid and cyclosporine A and/or cyclophosphamide.
  • No adverse reactions were seen due to IVIG treatment.
  • IVIG treatment is safe and could be an effective salvage therapy for refractory ILD-PM/DM in certain cases, suggesting that further controlled trials are worthwhile.
  • [MeSH-major] Dermatomyositis / drug therapy. Drug Resistance. Immunoglobulins, Intravenous / therapeutic use. Immunologic Factors / therapeutic use. Lung Diseases, Interstitial / drug therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Aged. Bronchoalveolar Lavage Fluid / immunology. Cyclosporine / therapeutic use. Female. Humans. Immunosuppressive Agents / therapeutic use. Male. Methotrexate / therapeutic use. Middle Aged. Retrospective Studies. Salvage Therapy. Tomography, X-Ray Computed. Treatment Outcome


57. Zabek M, Sobstyl M, Koziara H: [Deep brain stimulation of the Vim nucleus of the thalamus in the treatment of parkinsonian tremor]. Neurol Neurochir Pol; 2003 Mar-Apr;37(2):437-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Deep brain stimulation of the Vim nucleus of the thalamus in the treatment of parkinsonian tremor].
  • Deep brain stimulation (DBS) of the ventral intermediate thalamic nucleus (Vim) has been recently introduced by Benabid and his colleagues as a new surgical procedure in the treatment of tremor-dominant Parkinson's disease (PD).
  • In this procedure high-frequency stimulation is employed to simulate a thalamic lesion using an implanted electrode connected to a subcutaneously placed neuropacemaker.
  • There were 3 men and one women.
  • Chronic thalamic stimulation is effective for drug-resistance parkinsonian tremor suppression, with few adverse side-effects.
  • [MeSH-major] Electric Stimulation Therapy / instrumentation. Parkinson Disease / therapy. Thalamus / physiology. Ventral Thalamic Nuclei / physiology
  • [MeSH-minor] Female. Gait. Humans. Male. Middle Aged. Movement Disorders / diagnosis. Severity of Illness Index

  • Genetic Alliance. consumer health - Tremor.
  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14558490.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


58. Neglia D, Sambuceti G, Giorgetti A, Bartoli M, Salvadori P, Sorace O, Puccini G, L'Abbate A, Parodi O: Effects of long-term treatment with verapamil on left ventricular function and myocardial blood flow in patients with dilated cardiomyopathy without overt heart failure. J Cardiovasc Pharmacol; 2000 Dec;36(6):744-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of long-term treatment with verapamil on left ventricular function and myocardial blood flow in patients with dilated cardiomyopathy without overt heart failure.
  • We assessed the safety of long-term combination therapy of verapamil and enalapril and its effects on both left ventricular function and myocardial perfusion compared with enalapril alone in 18 patients with DCM (15 men, 3 women; mean age, 50+/-9 years) without overt heart failure (NYHA class I-II).
  • At baseline and after 6 months of randomized treatment with either enalapril (10-20 mg) (nine patients, group 1) or enalapril (10-20 mg) and verapamil (120-240 mg) (nine patients, group 2), left ventricular function was assessed at rest, during handgrip, and during bicycle exercise by equilibrium radionuclide angiography.
  • Mean MBF was measured at rest and after dipyridamole by positron emission tomography (PET) and 13N-ammonia as a flow tracer.
  • During treatment, no adverse events occurred in either group.
  • After 6 months there was no significant difference in the main study variables either between the two groups or within each group before and after treatment.
  • Long-term combination therapy with verapamil and enalapril is safe in patients with DCM without overt heart failure.
  • Despite no favorable effect on myocardial perfusion, combined treatment prevented deterioration of left ventricular function, similarly to enalapril alone.
  • [MeSH-major] Calcium Channel Blockers / pharmacology. Cardiomyopathy, Dilated / physiopathology. Coronary Circulation / drug effects. Ventricular Function, Left / drug effects. Verapamil / pharmacology
  • [MeSH-minor] Cardiac Output / drug effects. Double-Blind Method. Exercise Test. Female. Heart / radionuclide imaging. Heart Failure / physiopathology. Humans. Male. Middle Aged. Tomography, Emission-Computed

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • Genetic Alliance. consumer health - Dilated Cardiomyopathy.
  • Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11117374.001).
  • [ISSN] 0160-2446
  • [Journal-full-title] Journal of cardiovascular pharmacology
  • [ISO-abbreviation] J. Cardiovasc. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; CJ0O37KU29 / Verapamil
  •  go-up   go-down


59. Negoro A, Umemoto M, Nin T, Fujii M, Sakagami M: [Clinical experiences of the medication to taste disturbance by serum trace deficiency, especially serum iron deficiency]. Nihon Jibiinkoka Gakkai Kaiho; 2004 Mar;107(3):188-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical experiences of the medication to taste disturbance by serum trace deficiency, especially serum iron deficiency].
  • In the present study, we clinically investigated the relationship between taste disturbances and serum iron deficiency as well as the results of pharmacological therapy.
  • The clinical and serological test results of 25 patients with serum iron deficiency (3 men and 22 women; mean age +/- SD, 56.1 +/- 16.5 years) were reviewed at the Department of Otolaryngology, Hospital of Hyogo College of Medicine.
  • No significant difference in the results of treatment was seen, regardless of the duration of the deficiency.
  • These results suggest that treatment with iron and zinc medicine is useful for correcting taste disturbances caused by serum deficiencies of trace elements.
  • [MeSH-major] Iron / deficiency. Iron / therapeutic use. Taste Disorders / drug therapy. Taste Disorders / etiology
  • [MeSH-minor] Adult. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Taste Threshold. Treatment Outcome. Zinc / deficiency. Zinc / therapeutic use

  • MedlinePlus Health Information. consumer health - Iron.
  • MedlinePlus Health Information. consumer health - Taste and Smell Disorders.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15103944.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] E1UOL152H7 / Iron; J41CSQ7QDS / Zinc
  •  go-up   go-down


60. Stücker M, Memmel U, Hoffmann M, Hartung J, Altmeyer P: Vitamin B(12) cream containing avocado oil in the therapy of plaque psoriasis. Dermatology; 2001;203(2):141-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin B(12) cream containing avocado oil in the therapy of plaque psoriasis.
  • BACKGROUND: There are already many effective topical therapies available for use in the treatment of chronic plaque psoriasis.
  • Unfortunately, these treatments are often associated with a rather significant risk of undesirable effects.
  • OBJECTIVE AND METHODS: In this randomized, prospective clinical trial, the effects of the vitamin D(3) analog calcipotriol were evaluated against those of a recently developed vitamin B(12) cream containing avocado oil in an intraindividual right/left-side comparison.
  • The trial population consisted of 13 patients, 10 men and 3 women, with chronic plaque psoriasis.
  • The observation period was 12 weeks; the effects of therapy were assessed on the basis of a PASI score adapted to the right/left-side comparison technique, the subjective evaluations of the investigator and patients and the results of 20-MHz sonography.
  • RESULTS: There was a more rapid development of beneficial effects with the use of calcipotriol in the initial 8 weeks, although differences in effects were significant only at the time point of therapy week 8 (p < 0.05).
  • After 12 weeks, neither the PASI score nor 20-MHz sonography showed significant differences between the two treatments.
  • This would indicate that the vitamin B(12) preparation containing avocado oil may be suitable for use in long-term therapy, a hypothesis further supported by the fact that the investigator and the patients assessed the tolerability of the vitamin B(12) cream containing avocado oil as significantly better in comparison with that of calcipotriol.
  • CONCLUSION: The results of this clinical trial provide evidence that the recently developed vitamin B(12) cream containing avocado oil has considerable potential as a well-tolerated, long-term topical therapy of psoriasis.
  • [MeSH-major] Calcitriol / analogs & derivatives. Persea. Phytotherapy. Plant Oils / therapeutic use. Psoriasis / drug therapy. Vitamin B 12 / therapeutic use
  • [MeSH-minor] Adult. Aged. Dermatologic Agents / adverse effects. Dermatologic Agents / therapeutic use. Female. Humans. Male. Middle Aged. Ointments. Prospective Studies. Pruritus / chemically induced. Severity of Illness Index. Skin / drug effects. Skin / pathology. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11586013.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Ointments; 0 / Plant Oils; 143NQ3779B / calcipotriene; FXC9231JVH / Calcitriol; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


61. Midorikawa Y, Suzuki K, Motohashi G, Shimazaki J: [Review of our home parenteral nutrition (HPN) and home enteral nutrition (HEN) cases]. Gan To Kagaku Ryoho; 2003 Dec;30(1 Suppl):135-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We had 38 patients (26 men, 12 women) on HPN.
  • Of them, 23 (17 men, 6 women) had an implantable subcutaneous infusion port.
  • The average age of HPN cases was 69 (range 40-92) years, and 34 patients (89%) suffered from a malignant disease.
  • Home anti-cancer chemotherapy was provided for 2 patients.
  • Percutaneous gastrostomy was performed for 7 patients (4 men, 3 women) by endoscopy (PEG, 6 cases) and 1 patient needed an open laparotomy.
  • 5 patients with a malignant disease who were in HPN underwent gastrostomy for decompression drainage of a digestive tract obstruction.
  • 2 patients had a benign disease and were on HEN for a long time.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gastrostomy. Humans. Infusion Pumps, Implantable. Male. Middle Aged. Neoplasms / nursing. Quality of Life

  • MedlinePlus Health Information. consumer health - Home Care Services.
  • MedlinePlus Health Information. consumer health - Nutritional Support.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15311785.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


62. Moran SA, Patten N, Young JR, Cochran E, Sebring N, Reynolds J, Premkumar A, Depaoli AM, Skarulis MC, Oral EA, Gorden P: Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism; 2004 Apr;53(4):513-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy.
  • We studied 14 patients (3 men and 11 women); 12 of who had generalized lipodystrophy (7 congenital, 5 acquired), and 2 patients had partial lipodystrophy.
  • Body composition and related parameters were evaluated at baseline and after 4 and 12 months of leptin therapy.
  • On treatment, serum leptin levels increased by 10-fold.
  • All patients reported a decrease in appetite on therapy.
  • Dual energy x-ray absorptiometry (DEXA) demonstrated significant decreases in fat mass (5.4 +/- 0.8 kg to 5.0 +/- 0.8 kg; P =.003) and lean body mass (51.2 +/- 3.2 kg to 48.3 +/- 3.4 kg; P =.003) at 4 months on therapy.
  • There was no impact of leptin therapy on bone mineral content, mineral density, and metabolism.
  • Changes in body composition occurred during the first 4 months of leptin therapy, but then stabilized and were sustained thereafter.
  • [MeSH-major] Body Composition / drug effects. Leptin / therapeutic use. Lipodystrophy / drug therapy
  • [MeSH-minor] Absorptiometry, Photon. Adolescent. Adult. Aged. Anthropometry / methods. Bone Density / drug effects. Bone and Bones / drug effects. Bone and Bones / metabolism. Eating / drug effects. Eating / physiology. Energy Metabolism / drug effects. Energy Metabolism / physiology. Female. Humans. Liver / anatomy & histology. Liver / drug effects. Male. Middle Aged. Prospective Studies. Rest

  • Genetic Alliance. consumer health - Lipodystrophy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15045701.001).
  • [ISSN] 0026-0495
  • [Journal-full-title] Metabolism: clinical and experimental
  • [ISO-abbreviation] Metab. Clin. Exp.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


63. Mercuro G, Panzuto MG, Bina A, Leo M, Cabula R, Petrini L, Pigliaru F, Mariotti S: Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab; 2000 Jan;85(1):159-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring.
  • As recently claimed, TSH-suppressive therapy with L-T4 may have adverse effects on the heart, but these results have not been consistently confirmed.
  • We assessed cardiac function by clinical, echocardiographic, and ergometabolic criteria in 19 patients (16 women and 3 men) receiving long term L-T4 at a fixed daily dose ranging from 1.8-4.0 microg/kg.
  • In particular, intraventricular septum thickness (10.0+/-1.4 vs. 8.1+/-1.1 mm), left ventricular posterior wall thickness (9.4 1.5 vs. 8.1+/-1.1 mm), end-diastolic dimension (47+/-4 vs. 44+/-3 mm), and left ventricular mass index (102+/-15 vs. 75+/-15 g/m2) were significantly increased compared to values in age- and sex-matched euthyroid controls.
  • In conclusion, our findings show that abnormalities of heart morphology associated with impaired exercise performance occur as a consequence of long term therapy with fixed TSH-suppressive doses of L-T4, but that these abnormalities improve or disappear after careful tailoring of TSH-suppressive therapy.
  • [MeSH-major] Exercise / physiology. Heart / drug effects. Hyperthyroidism / drug therapy. Quality of Life. Thyrotropin / antagonists & inhibitors. Thyroxine / administration & dosage. Thyroxine / therapeutic use
  • [MeSH-minor] Adult. Aged. Electrocardiography / drug effects. Exercise Test. Female. Hemodynamics / drug effects. Humans. Long-Term Care. Longitudinal Studies. Male. Middle Aged. Sympathetic Nervous System / physiopathology


64. Al-Rawi M, Wheeler MH: Medullary thyroid carcinoma--update and present management controversies. Ann R Coll Surg Engl; 2006 Sep;88(5):433-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are still many controversial aspects relating to the diagnosis and management of this unusual tumour in its various forms.
  • RESULTS: Genetically determined tumours constitute approximately 25% of MTC and have special clinical interest because of their association with other endocrinopathies including phaeochromocytoma and hyperparathyroidism in the multiple endocrine neoplasia syndromes (MEN IIa and MEN IIb).
  • MTC is a tumour which does not take up radioactive iodine, is relatively radioresistant and poorly responsive to chemotherapy.
  • Therefore, surgery is the only treatment which can offer the prospect of cure.
  • Compartmental orientated microdissection of cervical nodes has significantly improved the results of primary surgery but even so a group of 20% of patients will prove to have recurrent or residual disease.
  • These cases require detailed investigation by a variety of techniques including ultrasound, cross-sectional imaging, nuclear imaging and laparoscopy with liver biopsy to exclude disseminated disease and select those patients who can be offered a prospect of cure by further neck surgery.
  • CONCLUSIONS: It is hoped that in the near future new medical therapies may become available to treat MTC which still has a 10-year survival of only 60-80% in spite of the application of meticulous surgical techniques.
  • [MeSH-major] Carcinoma, Medullary / surgery. Thyroid Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2000 Aug;24(8):952-6 [10865039.001]
  • [Cites] Ann Surg. 1997 Jun;225(6):734-40; discussion 740-3 [9230814.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1073-5 [12190669.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1023-8 [12016484.001]
  • [Cites] World J Surg. 2004 Apr;28(4):397-401 [14994142.001]
  • [Cites] J Clin Pathol. 1966 Mar;19(2):114-8 [5948665.001]
  • [Cites] Proc R Soc Med. 1966 Jul;59(7):602-3 [5939499.001]
  • [Cites] Surg Clin North Am. 1977 Aug;57(4):633-45 [897960.001]
  • [Cites] Trans Assoc Am Physicians. 1979;92:286-91 [44926.001]
  • [Cites] Surgery. 1986 Jan;99(1):60-6 [3942001.001]
  • [Cites] Ann Surg. 1990 Oct;212(4):395-400; discussion 400-1 [2222011.001]
  • [Cites] Am J Med. 1997 Jul;103(1):60-9 [9236487.001]
  • [Cites] Surgery. 1997 Dec;122(6):1124-30; discussion 1130-1 [9426428.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 1998;106(1):29-34 [9516056.001]
  • [Cites] World J Surg. 1998 Jun;22(6):562-7; discussion 567-8 [9597929.001]
  • [Cites] World J Surg. 1998 Jul;22(7):744-50; discussion 750-1 [9606292.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):880-7; discussion 887-8 [10363903.001]
  • [Cites] J Clin Endocrinol Metab. 1959 Jan;19(1):152-61 [13620740.001]
  • [Cites] Br J Surg. 2005 May;92(5):574-8 [15779075.001]
  • [Cites] World J Surg. 2005 Apr;29(4):472-82 [15776290.001]
  • [Cites] Nature. 1993 Jun 3;363(6428):458-60 [8099202.001]
  • [Cites] Hum Mol Genet. 1993 Jul;2(7):851-6 [8103403.001]
  • [Cites] Surgery. 1993 Dec;114(6):1090-5; discussion 1095-6 [8256212.001]
  • [Cites] Nat Genet. 1994 Jan;6(1):70-4 [7907913.001]
  • [Cites] Surg Today. 1994;24(2):112-21 [8054788.001]
  • [Cites] N Engl J Med. 1994 Sep 29;331(13):828-35 [7915822.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):237-47; discussion 247-50 [7916559.001]
  • [Cites] Surgery. 1994 Dec;116(6):1017-23 [7985081.001]
  • [Cites] J Endocrinol Invest. 1995 Mar;18(3):180-5 [7615903.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Feb;82(2):338-41 [9024213.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1367-72 [11038208.001]
  • (PMID = 17002842.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  • [Other-IDs] NLM/ PMC1964684
  •  go-up   go-down


65. Donaldson MG, Cawthon PM, Lui LY, Schousboe JT, Ensrud KE, Taylor BC, Cauley JA, Hillier TA, Dam TT, Curtis JR, Black DM, Bauer DC, Orwoll ES, Cummings SR, Osteoporotic Fractures in Men (MrOS) Study Group: Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res; 2010 Jul;25(7):1506-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines.
  • The new US National Osteoporosis Foundation's (NOF's) Clinician's Guide to Prevention and Treatment of Osteoporosis includes criteria for recommending pharmacologic treatment based on history of hip or vertebral fracture, femoral neck or spine bone mineral density (BMD) T-scores of -2.5 or less, and presence of low bone mass at the femoral neck or spine plus a 10-year risk of hip fracture of 3% or greater or of major osteoporotic fracture of 20% or greater.
  • The proportion of men who would be recommended for treatment by these guidelines is not known.
  • We applied the NOF criteria for treatment to men participating in the Osteoporotic Fractures in Men Study (MrOS).
  • To determine how the MrOS population differs from the general US population of Caucasian men aged 65 years and older, we compared men in MrOS with men who participated in the National Health and Nutrition Examination Survey (NHANES) III on criteria included in the NOF treatment guidelines that were common to both cohorts.
  • Compared with NHANES III, men in MrOS had higher femoral neck BMD values.
  • Application of NOF guidelines to MrOS data estimated that at least 34% of US white men aged 65 years and older and 49% of those aged 75 years and older would be recommended for drug treatment.
  • Application of the new NOF guidelines would result in recommending a very large proportion of white men in the United States for pharmacologic treatment of osteoporosis, for many of whom the efficacy of treatment is unknown.

  • Genetic Alliance. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 American Society for Bone and Mineral Research.
  • [Cites] N Engl J Med. 2000 Aug 31;343(9):604-10 [10979796.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3069-76 [10999788.001]
  • [Cites] J Bone Miner Res. 2003 Jan;18(1):9-17 [12510800.001]
  • [Cites] Rheumatol Int. 2004 Mar;24(2):110-3 [13680141.001]
  • [Cites] Osteoporos Int. 1998;8(5):468-89 [9850356.001]
  • [Cites] Contemp Clin Trials. 2005 Oct;26(5):569-85 [16084776.001]
  • [Cites] Contemp Clin Trials. 2005 Oct;26(5):557-68 [16085466.001]
  • [Cites] Rheumatol Int. 2006 Mar;26(5):427-31 [16001181.001]
  • [Cites] J Bone Miner Res. 2006 Oct;21(10):1550-6 [16995809.001]
  • [Cites] J Bone Miner Res. 2007 Feb;22(2):228-34 [17129177.001]
  • [Cites] Ann Intern Med. 2008 Feb 5;148(3):197-213 [18087050.001]
  • [Cites] Osteoporos Int. 2008 Apr;19(4):437-47 [18292976.001]
  • [Cites] Osteoporos Int. 2008 Apr;19(4):385-97 [18292978.001]
  • [Cites] J Bone Miner Res. 2009 Apr;24(4):719-25 [19049326.001]
  • [Cites] J Bone Miner Res. 2009 Apr;24(4):675-80 [19049330.001]
  • (PMID = 20200971.001).
  • [ISSN] 1523-4681
  • [Journal-full-title] Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • [ISO-abbreviation] J. Bone Miner. Res.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / U01 AR45632; United States / NIAMS NIH HHS / AR / U01 AR45647; United States / NIAMS NIH HHS / AR / U01 AR45614; United States / NIAMS NIH HHS / AR / U01 AR045614; United States / NIAMS NIH HHS / AR / U01 AR45654; United States / NIAMS NIH HHS / AR / U01 AR045654; United States / NIA NIH HHS / AG / U01-AG027810; United States / NIAMS NIH HHS / AR / U01 AR045583; United States / NIA NIH HHS / AG / U01 AG042140; United States / NIAMS NIH HHS / AR / U01 AR45583; United States / NIAMS NIH HHS / AR / U01 AR045647; United States / NIAMS NIH HHS / AR / U01 AR45580; United States / NIA NIH HHS / AG / U01 AG027810; United States / NCRR NIH HHS / RR / UL1 RR024140; United States / NIAMS NIH HHS / AR / U01 AR045580; United States / NIA NIH HHS / AG / U01 AG18197; United States / NIA NIH HHS / AG / U01 AG018197; United States / NIAMS NIH HHS / AR / U01 AR045632
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3153995
  •  go-up   go-down


66. Chartier-Kastler E, Azouvi P, Yakovleff A, Bussel B, Richard F, Denys P: Intrathecal catheter with subcutaneous port for clonidine test bolus injection. A new route and type of treatment for detrusor hyperreflexia in spinal cord-injured patients. Eur Urol; 2000 Jan;37(1):14-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathecal catheter with subcutaneous port for clonidine test bolus injection. A new route and type of treatment for detrusor hyperreflexia in spinal cord-injured patients.
  • METHODS: According to approval of the local ethics committee, 9 consecutive SCI patients (6 men, 3 women) had catheter and port implantation between January 1998 and May 1999.
  • All did not respond to systemic drug therapy in combination to self-clean intermittent catheterisation (SCIC).
  • After clonidine bolus injection test and validation, 6 patients decided to have permanent pump implantation, 2 chose other therapies and one did not tolerate clonidine intrathecal injections for blood arterial pressure side effects.
  • CONCLUSIONS: Intrathecal clonidine may represent a useful conservative treatment of both severe bladder hyperreflexia and spinal spasticity.
  • Its short-term effects can be individually evaluated through bolus injection in subcutaneous port before definitive pump implantation.
  • [MeSH-major] Catheters, Indwelling. Clonidine / administration & dosage. Spinal Cord Injuries / complications. Sympatholytics / administration & dosage. Urinary Bladder Diseases / drug therapy. Urinary Bladder Diseases / etiology
  • [MeSH-minor] Adult. Feasibility Studies. Female. Humans. Male. Middle Aged. Muscle, Smooth / drug effects. Muscle, Smooth / physiopathology. Reflex, Abnormal / drug effects. Spine

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • Hazardous Substances Data Bank. CLONIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10671778.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 0 / Sympatholytics; MN3L5RMN02 / Clonidine
  •  go-up   go-down


67. Schulman EA, Dermott KF: Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache; 2003 Jul-Aug;43(7):729-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: We evaluated the effectiveness of combination treatment using sumatriptan plus metoclopramide versus sumatriptan alone for the treatment of acute migraine.
  • METHODS: In this double-blind, randomized, crossover study, 16 adult migraineurs fulfilling International Headache Society (IHS) criteria for migraine with or without aura who had failed to receive adequate relief from triptans treated one migraine with each treatment: sumatriptan 50 mg plus metoclopramide 10 mg or sumatriptan 50 mg plus placebo to match metoclopramide.
  • Patients treated their migraines when they were moderate or severe in intensity and recorded pain severity and symptoms prior to treatment and 30, 60, 90, and 120 minutes and 24 hours after treatment.
  • RESULTS: Thirteen women and 3 men (mean age, 40 years) completed the study; ie, treated 2 migraines (a total of 32 migraines), one attack with each treatment.
  • There did not appear to be a difference between treatment groups with respect to associated symptoms.
  • It remains unknown whether initiating therapy when pain was mild or using a higher dose of sumatriptan (ie, 100 mg) would have provided additional benefit.
  • [MeSH-major] Antiemetics / therapeutic use. Metoclopramide / therapeutic use. Migraine Disorders / drug therapy. Serotonin Receptor Agonists / therapeutic use. Sumatriptan / therapeutic use
  • [MeSH-minor] Adult. Double-Blind Method. Drug Combinations. Female. Humans. Male. Middle Aged. Pilot Projects. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Migraine.
  • Hazardous Substances Data Bank. Sumatriptan .
  • Hazardous Substances Data Bank. Metoclopramide .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Headache. 2004 May;44(5):446-7 [15147257.001]
  • (PMID = 12890127.001).
  • [ISSN] 0017-8748
  • [Journal-full-title] Headache
  • [ISO-abbreviation] Headache
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiemetics; 0 / Drug Combinations; 0 / Serotonin Receptor Agonists; 8R78F6L9VO / Sumatriptan; L4YEB44I46 / Metoclopramide
  •  go-up   go-down


68. McDowell DM, Levin FR, Seracini AM, Nunes EV: Venlafaxine treatment of cocaine abusers with depressive disorders. Am J Drug Alcohol Abuse; 2000 Feb;26(1):25-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Venlafaxine treatment of cocaine abusers with depressive disorders.
  • The purpose of this study was to examine the effect of venlafaxine, a broad spectrum antidepressant, in the treatment of 13 patients who were diagnosed with cocaine dependence and comorbid major depressive disorder (MDD).
  • Thirteen patients were enrolled, 10 men and 3 women.
  • In addition, all of the patients received weekly relapse prevention therapy throughout the study.
  • RESULTS: The 11 patients who completed the study had significant reductions in mood symptoms by the end of the study.
  • The average total HAM-D score at baseline was 18.0 +/- 3.2; at Week 2, it was 1.9 +/- 0.94; and at the end of the study, it was 1.4 +/- 1.8.
  • CONCLUSIONS: The results of this small study indicate that venlafaxine may be a safe, well-tolerated, rapidly acting, and effective treatment for patients with a dual diagnosis of depression and cocaine dependence.
  • [MeSH-major] Antidepressive Agents, Second-Generation / therapeutic use. Cocaine-Related Disorders / rehabilitation. Cyclohexanols / therapeutic use. Depressive Disorder, Major / rehabilitation
  • [MeSH-minor] Adult. Comorbidity. Desipramine / adverse effects. Desipramine / therapeutic use. Diagnosis, Dual (Psychiatry). Double-Blind Method. Female. Humans. Male. Middle Aged. Pilot Projects. Treatment Failure. Venlafaxine Hydrochloride

  • MedlinePlus Health Information. consumer health - Cocaine.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DESIPRAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10718161.001).
  • [ISSN] 0095-2990
  • [Journal-full-title] The American journal of drug and alcohol abuse
  • [ISO-abbreviation] Am J Drug Alcohol Abuse
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antidepressive Agents, Second-Generation; 0 / Cyclohexanols; 7D7RX5A8MO / Venlafaxine Hydrochloride; TG537D343B / Desipramine
  •  go-up   go-down


69. Kuriyama S, Ohashi R, Matsuda K, Sugano K, Muraki K, Minakata K, Ishiwata T, Hirama M, Kodama Y, Oh S, Suzuki K, Takahashi K: [Twelve cases of advanced thymic carcinoma: a clinical review]. Nihon Kokyuki Gakkai Zasshi; 2010 Aug;48(8):604-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thymic carcinoma is comparatively rare and no standard treatment has been established for advanced stage cases.
  • We reviewed our therapeutic experience in 12 cases of thymic carcinoma.
  • They consisted of 9 men and 3 women, ranging from 38 to 69 years of age, with a mean age of 56.5.
  • According to Masaoka's classification, 5 cases were stage III and 7 were preoperative stage IVb.
  • Four cases of preoperative clinical stage III underwent extended thymectomy, but none were completely resected and were classified as stage IV postoperatively.
  • Chemotherapy combined with radiation therapy was given in 1 case, chemotherapy (monotherapy) was given in 4 cases, radiation therapy was given in 1 case, and 2 cases received best supportive care.
  • The median survival time (MST) of patients who had undergone combined modality treatments including surgery was 1971 days, which was longer than the MST of 567 days of patients who were not able to undergo surgery.
  • The prognosis outcome of advanced thymic carcinoma is poor, but combined modality therapies such as surgery, chemotherapy and radiation can be effective for some advanced thymic carcinoma cases.
  • [MeSH-major] Adenocarcinoma / therapy. Carcinoma, Squamous Cell / therapy. Thymus Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20803979.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


70. Hinson VK, Goetz CG, Leurgans S, Fan W, Nguyen T, Hsu A: Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol; 2009 Jul-Aug;32(4):189-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
  • OBJECTIVE: We compared IPX054, a bilayer tablet of immediate- and extended-release carbidopa/levodopa (CD/LD) given twice daily to standard CD/LD given 4 times daily in patients with stable Parkinson disease (PD).
  • METHODS: Twelve PD patients with no or mild fluctuations on CD/LD 25/100 mg 4 times daily were randomized to a double-blind crossover comparison with IPX054 (50/200 mg) twice daily.
  • At the end of each 2-week treatment, patients were video recorded while performing a modified Unified Parkinson's Disease Rating Scale motor examination and Rush Dyskinesia Rating Scale at 30-minute intervals over 8.5 hours.
  • RESULTS: The 9 men and 3 women had a mean age of 69 years and mean PD duration of 6 years.
  • The mean time to ON was improved with IPX054 (P = 0.014), and the mean modified Unified Parkinson's Disease Rating Scale scores slightly favored IPX054 (14.4 vs 16.9; P = 0.052).
  • No patient developed troublesome dyskinesias.
  • CONCLUSIONS: In stable PD patients, no difference was detected between twice-daily treatment with IPX054 and CD/LD given 4 times daily.
  • In clinical practice, this ease of administration may offer improved treatment compliance.
  • [MeSH-major] Antiparkinson Agents / administration & dosage. Carbidopa / administration & dosage. Levodopa / administration & dosage. Parkinson Disease / drug therapy
  • [MeSH-minor] Activities of Daily Living. Aged. Cross-Over Studies. Double-Blind Method. Drug Administration Schedule. Drug Combinations. Dyskinesias / drug therapy. Dyskinesias / physiopathology. Female. Humans. Male. Movement / drug effects. Movement / physiology. Tablets. Videotape Recording

  • Genetic Alliance. consumer health - Parkinson Disease.
  • Genetic Alliance. consumer health - Parkinson disease 4.
  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620848.001).
  • [ISSN] 1537-162X
  • [Journal-full-title] Clinical neuropharmacology
  • [ISO-abbreviation] Clin Neuropharmacol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiparkinson Agents; 0 / Drug Combinations; 0 / Tablets; 46627O600J / Levodopa; MNX7R8C5VO / Carbidopa
  •  go-up   go-down


71. Quayle FJ, Moley JF: Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes. J Surg Oncol; 2005 Mar 1;89(3):122-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes.
  • First, MTC may be sporadic (75% of cases), or may occur as a manifestation of the hereditary syndrome Multiple Endocrine Neoplasia type 2 (MEN 2) (25% of cases).
  • Finally, unlike differentiated thyroid cancer, there is no known effective systemic therapy for MTC.
  • MTC cells do not concentrate radioactive iodine, and MTC does not respond well to external beam radiation or conventional cytotoxic chemotherapy.
  • [MeSH-major] Carcinoma, Medullary. Multiple Endocrine Neoplasia Type 2a. Multiple Endocrine Neoplasia Type 2b. Thyroid Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Calcitonin / blood. Combined Modality Therapy. Dacarbazine / administration & dosage. Endocrine Surgical Procedures / methods. Fluorouracil / administration & dosage. Humans. Lymph Node Excision. Mutation. Parathyroidectomy. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-ret. Receptor Protein-Tyrosine Kinases / genetics. Thyroidectomy. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15719378.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 7GR28W0FJI / Dacarbazine; 9007-12-9 / Calcitonin; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; U3P01618RT / Fluorouracil
  • [Number-of-references] 56
  •  go-up   go-down


72. Aiba T, Suyama K, Aihara N, Taguchi A, Shimizu W, Kurita T, Kamakura S: The role of Purkinje and pre-Purkinje potentials in the reentrant circuit of verapamil-sensitive idiopathic LV tachycardia. Pacing Clin Electrophysiol; 2001 Mar;24(3):333-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Electrophysiological studies and radiofrequency catheter ablation were performed in ten patients (7 men, 3 women, mean age 29 years) who had an ILVT with a right bundle branch block configuration and left-axis deviation.
  • The earliest PP during VT was recorded at the inferoposterior septum, and PP was activated bidirectionally toward the proximal (basal) and distal (apical) sites along the left posterior fascicle.
  • The pre-PP was orthodromically activated from the proximal to the distal site during pacing.
  • [MeSH-major] Calcium Channel Blockers / pharmacology. Heart Conduction System / physiopathology. Purkinje Fibers / physiopathology. Tachycardia, Ventricular / physiopathology. Ventricular Dysfunction, Left / drug therapy. Ventricular Dysfunction, Left / physiopathology. Verapamil / pharmacology
  • [MeSH-minor] Adolescent. Adult. Bundle-Branch Block / drug therapy. Bundle-Branch Block / physiopathology. Bundle-Branch Block / surgery. Catheter Ablation. Electrocardiography. Female. Follow-Up Studies. Humans. Male. Treatment Outcome

  • Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11310303.001).
  • [ISSN] 0147-8389
  • [Journal-full-title] Pacing and clinical electrophysiology : PACE
  • [ISO-abbreviation] Pacing Clin Electrophysiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; CJ0O37KU29 / Verapamil
  •  go-up   go-down


73. Gorla L, Mondellini P, Cuccuru G, Miccichè F, Cassinelli G, Cremona M, Pierotti MA, Lanzi C, Bongarzone I: Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements. Mol Carcinog; 2009 Mar;48(3):220-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Proteomics may help to elucidate differential signaling networks underlying the effects of compounds and to identify new therapeutic targets.
  • Using a proteomic-multiplexed analysis of the phosphotyrosine signaling together with antibody-based validation techniques, we identified several candidate molecules for RET (rearranged during transfection) tyrosine kinase receptor carrying mutations responsible for the multiple endocrine neoplasia type 2A and 2B (MEN2A and MEN2B) syndromes in two human medullary thyroid carcinoma (MTC) cell lines, TT and MZ-CRC-1, which express the RET-MEN2A and RET-MEN2B oncoproteins, respectively.
  • We detected 23 and 18 affinity-purified phosphotyrosine proteins in untreated TT and MZ-CRC-1 cells, respectively, most of which were shared and sensitive to RPI-1 treatment.
  • However, our data clearly point to specific signaling features of the RET-MEN2A and RET-MEN2B oncogenic pathways.
  • Moreover, the detection of high-level expression of minimally phosphorylated epidermal growth factor receptor (EGFR) in both TT and MZ-CRC-1 cells, together with our data on the effects of EGF stimulation on the proteomic profiles and the response to Gefitinib treatment, suggest the relevance of EGFR signaling in these cell lines, especially since analysis of 14 archival MTC specimens revealed EGFR mRNA expression in all samples.
  • Together, our data suggest that RET/EGFR multi-target inhibitors might be beneficial for therapy of MTC.
  • [MeSH-major] Germ-Line Mutation / genetics. Oncogene Proteins / metabolism. Proteomics. Proto-Oncogene Proteins c-ret / genetics. Proto-Oncogene Proteins c-ret / metabolism. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Carcinoma, Medullary / drug therapy. Carcinoma, Medullary / genetics. Carcinoma, Medullary / metabolism. Epidermal Growth Factor / pharmacology. Female. Humans. Mice. Mice, Nude. Multiple Endocrine Neoplasia Type 2a / drug therapy. Multiple Endocrine Neoplasia Type 2a / genetics. Multiple Endocrine Neoplasia Type 2a / metabolism. Multiple Endocrine Neoplasia Type 2b / drug therapy. Multiple Endocrine Neoplasia Type 2b / genetics. Multiple Endocrine Neoplasia Type 2b / metabolism. Phosphorylation / drug effects. Quinazolines / pharmacology. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. Signal Transduction. Tyrosine / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18756447.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Oncogene Proteins; 0 / Quinazolines; 42HK56048U / Tyrosine; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


74. Kusumoto S, Hirose T, Fukayama M, Kataoka D, Hamada K, Sugiyama T, Shirai T, Yamaoka T, Okuda K, Ohnishi T, Ohmori T, Kadokura M, Adachi M: Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer. Oncol Rep; 2009 Nov;22(5):1157-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thoracic radiotherapy (2 Gy per fraction; total dose, 40 Gy) was given concurrently.
  • Surgical resection was performed after induction therapy had been completed.
  • If disease was considered clinically inoperable after induction therapy, patients received 2 additional cycles of the chemotherapy and 20 Gy of additional radiotherapy.
  • Twenty-three patients (20 men and 3 women; median age, 63 years; age range, 45-72 years) were enrolled.
  • There were no treatment-related deaths.
  • The median survival time was 36 months (range, 4-78 months), the 2-year survival rate was 74%, and the median time to disease progression was 15 months (range, 2-59 months).
  • This trimodality therapy is effective and well tolerated and is an acceptable therapeutic option for patients with locally advanced NSCLC.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Squamous Cell / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Prognosis. Radiotherapy Dosage. Remission Induction. Survival Rate. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives. Young Adult


75. Rosato L, Mondini G, Serbelloni M, Bertone P, Orlassino R, Cossavella D: [Intra-abdominal desmoid tumors: rare but important disease]. G Chir; 2007 Jan-Feb;28(1-2):20-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intra-abdominal desmoid tumors: rare but important disease].
  • Desmoid tumors are rare benign neoplasms with high tendency to local recurrence, and they can be divided into extra- and intra-abdominal types (mesenteric fibromatosis).
  • Six patients (3 men and 3 women) affected by extra-abdominal desmoid tumors have been treated with radical excision.
  • In both cases the hystological diagnosis has been desmoid tumor.
  • Surgical treatment of desmoid tumors must aim at radical excision to avoid frequent recurrences (25-65%); these have stimulated the research of other kinds of treatments, since a new surgical operation itself can lead to a further recurrence.
  • Radiotherapy has been investigated with results in 79-96% of cases, antiestrogenic therapy has been used with success in 51% of patients, and high dose tamoxifen seemed to obtain a stable disease in non operable cases.
  • Non steroidal anti-inflammatory drugs have been experimented in association with tamoxifen and chemotherapy.
  • Conclusive results on the efficacy of these treatments have not been obtained yet, because of the rarity of the desmoid tumors even in greater Centres.
  • [MeSH-major] Fibromatosis, Abdominal / surgery. Mesentery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Aged. Female. Fibromatosis, Aggressive / surgery. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313728.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


76. Kinuya K, Matano S, Nakashima H, Taki S: Scintigraphic prediction of therapeutic outcomes of splenectomy in patients with thrombocytopenia. Ann Nucl Med; 2003 Apr;17(2):161-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scintigraphic prediction of therapeutic outcomes of splenectomy in patients with thrombocytopenia.
  • METHODS: Platelet scintigraphy was performed in five patients (2 women, 3 men, mean age 48 years) before splenectomy.
  • Four patients were diagnosed with idiopathic thrombocytopenic purpura and one with hypersplenism due to portal hypertension caused by intrahepatic chemotherapy against metastatic liver tumors of rectal cancer.
  • CONCLUSION: The results of this study indicate that platelet scintigraphy is of value in predicting the therapeutic efficacy of splenectomy in patients with thrombocytopenia.
  • [MeSH-minor] Adult. Feasibility Studies. Female. Humans. Male. Middle Aged. Platelet Count. Predictive Value of Tests. Prognosis. Radiopharmaceuticals. Spleen / blood supply. Spleen / radionuclide imaging. Spleen / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12790368.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 3B744AG22N / Technetium Tc 99m Exametazime
  •  go-up   go-down


77. Smith SR, Som P, Fahmy A, Lawson W, Sacks S, Brandwein M: A clinicopathological study of sinonasal neuroendocrine carcinoma and sinonasal undifferentiated carcinoma. Laryngoscope; 2000 Oct;110(10 Pt 1):1617-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological and immunohistochemical findings, patient demographics, treatment regimens, and outcomes were analyzed and compared.
  • RESULTS: Ten patients (7 men, 3 women) ranging in age from 17 to 58 years (mean age, 44.7 y) were included.
  • Disease in four patients was clinically staged as N1 (three with SNUC, one with SNEC), and in six patients as NO (three with SNEC, three with SNUC).
  • Of the nine patients who were treated initially with surgical resection, seven received postoperative radiation therapy alone, one received postoperative radiation and chemotherapy, and one had only limited postoperative chemotherapy.
  • One patient was treated with radiation therapy and chemotherapy alone, without surgical resection.
  • Three patients died of disease 10, 14, and 41 months, respectively, after diagnosis.
  • Three patients had persistent disease at 6, 9, and 21 months, respectively, two of them with distant metastases.
  • Four patients were disease free after 6, 18, 31, and 108 months, respectively.
  • CONCLUSIONS: SNUC and SNEC are both aggressive tumors, usually presenting in middle age as a nasal mass.
  • Both tumors have the capacity to metastasize locally and distantly, and both can result in poor outcomes.
  • [MeSH-major] Carcinoma / pathology. Nose Neoplasms / pathology. Paranasal Sinuses
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11037813.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


78. Pitche P, Mouzou T, Padonou C, Tchangai-Walla K: [Stevens-Johnson syndrome and toxic epidermal necrolysis after intake of rifampicin-isoniazid: report of 8 cases in HIV-infected patients in Togo]. Med Trop (Mars); 2005 Sep;65(4):359-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stevens-Johnson syndrome and toxic epidermal necrolysis after intake of rifampicin-isoniazid: report of 8 cases in HIV-infected patients in Togo].
  • [Transliterated title] Syndromes de Stevens-Johnson et de lyell après la prise de rifampicine-isoniazide chez 8 malades infectés par le VIH au Togo.
  • Dermatological reactions are frequent drug-related complications in patients with HIV infection.
  • The most serious disorders are Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), a.k.a.
  • Lyell's syndrome, that are potentially fatal.
  • There were 5 men and 3 women with a mean age of 28 years.
  • The disorder was SJS in 3 cases and TEN in 5.
  • In 6 cases, manifestations occurred during initiation of treatment (mean delay for onset, 16 days).
  • In the remaining two cases, manifestations occurred 6 days and 8 days respectively after beginning treatment for recurrent tuberculosis.
  • This study documents incrimination of combined rifampin-isoniazid treatment in the occurrence of SJS/TEN in patients with HIV infection and confirms the severity and poor prognosis of these disorders.
  • [MeSH-major] Antitubercular Agents / adverse effects. Isoniazid / adverse effects. Rifampin / adverse effects. Stevens-Johnson Syndrome / chemically induced. Stevens-Johnson Syndrome / etiology. Tuberculosis, Miliary / drug therapy. Tuberculosis, Pulmonary / drug therapy
  • [MeSH-minor] Adult. Antibiotics, Antitubercular / adverse effects. Antibiotics, Antitubercular / therapeutic use. Drug Therapy, Combination. Female. HIV Infections / drug therapy. Humans. Male. Togo

  • Genetic Alliance. consumer health - Stevens-Johnson syndrome.
  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. RIFAMPIN .
  • Hazardous Substances Data Bank. ISONIAZID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16548490.001).
  • [ISSN] 0025-682X
  • [Journal-full-title] Médecine tropicale : revue du Corps de santé colonial
  • [ISO-abbreviation] Med Trop (Mars)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibiotics, Antitubercular; 0 / Antitubercular Agents; V83O1VOZ8L / Isoniazid; VJT6J7R4TR / Rifampin
  •  go-up   go-down


79. Logue JP, Harris MA, Livsey JE, Swindell R, Mobarek N, Read G: Short course para-aortic radiation for stage I seminoma of the testis. Int J Radiat Oncol Biol Phys; 2003 Dec 1;57(5):1304-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To determine the outcome in men with Stage I seminoma treated with low-dose para-aortic radiation.
  • MATERIALS AND METHODS: Between January 1988 and December 2000, 431 men with Stage I seminoma were treated with para-aortic radiation to a midplane dose of 20 Gy in 8 fractions over 10 days.
  • RESULTS: At a median follow-up of 62 months, 15 patients (3.5%) had relapsed, with a median time to relapse of 13 months (range: 9 to 39 months).
  • Nine patients had pelvic nodal relapse; in addition, 1 patient had para-aortic involvement, and 2 had distant disease.
  • Four had metastatic disease only (mediastinum 2, lung 2).
  • One patient had scrotal recurrence, and 1 was treated for progressive rise in human chorionic gonadotrophin without identifiable disease.
  • Initial treatment at relapse was chemotherapy (12), radiation (2), and surgery (1).
  • One patient died from progressive disease.
  • Thirteen men (3%) have developed second malignancies, including 7 contralateral testicular tumors, 5 solid malignancies, and 1 leukemia.
  • [MeSH-major] Seminoma / radiotherapy. Testicular Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / etiology

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14630266.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Shiraishi Y, Nakajima Y, Katsuragi N, Kurai M, Takahashi N: Pneumonectomy for nontuberculous mycobacterial infections. Ann Thorac Surg; 2004 Aug;78(2):399-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pneumonectomy is considered in the treatment of nontuberculous mycobacterial infections when an entire lung is affected.
  • However, this procedure carries high morbidity.
  • Of these patients, 11 (3 men, 8 women) underwent pneumonectomy (5 right, 6 left).
  • Mycobacterium avium complex disease occurred in 10 patients and Mycobacterium abscessus disease in 1.
  • Indications for pneumonectomy included multiple cavities in one lung and destruction of an entire lung.
  • RESULTS: Operating time ranged from 142 to 477 minutes (median, 360 minutes).
  • A second patient, the only patient who had recurrent disease, died of respiratory failure 4 years postoperatively.
  • [MeSH-minor] Adult. Aged. Anti-Bacterial Agents. Antitubercular Agents / therapeutic use. Blood Loss, Surgical. Bronchial Fistula / epidemiology. Bronchial Fistula / etiology. Combined Modality Therapy. Drug Therapy, Combination / therapeutic use. Female. Fistula / epidemiology. Fistula / etiology. Humans. Male. Middle Aged. Mycobacterium Infections / drug therapy. Mycobacterium Infections / surgery. Pleural Diseases / epidemiology. Pleural Diseases / etiology. Postoperative Complications / epidemiology. Postoperative Complications / etiology. Recurrence. Respiratory Insufficiency / mortality. Retrospective Studies. Surgical Flaps. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15276484.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antitubercular Agents
  • [Number-of-references] 16
  •  go-up   go-down


81. Karmouni T, Rioux-Leclercq N, Bensalah K, Alva A, Patard JJ, Guillé F, Lobel B: [Primary neuroendocrine carcinoma of the bladder: diagnosis and treatment]. Prog Urol; 2000 Sep;10(4):590-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary neuroendocrine carcinoma of the bladder: diagnosis and treatment].
  • [Transliterated title] Carcinomes neuroendocrines primitifs de vessie: diagnostic et traitement.
  • This study analyzed the diagnostic criteria and therapeutic results obtained in 5 consecutive patients over a 3-year period.
  • MATERIALS AND METHODS: 5 patients (3 men and 2 women) suffering from primary small cell carcinoma of the bladder were evaluated.
  • Histological diagnosis, treatment modalities and outcome were reviewed.
  • All tumours were invasive at the time of diagnosis.
  • 4 patients were treated by trans urethral resection alone, 2 of whom also received adjuvant radio-chemotherapy.
  • The 4 patients treated by conservative treatment modality had progression and a shorter survival, in contrast with patient treated by radical cystectomy.
  • Treatment must consist of a combination of neoadjuvant or adjuvant chemotherapy and surgery to achieve the best results.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / therapy. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11064903.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] FRANCE
  •  go-up   go-down


82. García-Peris P, Lozano MA, Velasco C, de La Cuerda C, Iriondo T, Bretón I, Camblor M, Navarro C: Prospective study of resting energy expenditure changes in head and neck cancer patients treated with chemoradiotherapy measured by indirect calorimetry. Nutrition; 2005 Nov-Dec;21(11-12):1107-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The prevalence of malnutrition is high in patients with head and neck cancer due to tumor location and coadjuvant treatment.
  • We studied changes in resting energy expenditure (REE) during treatment with chemoradiotherapy and compared the measured REE by indirect calorimetry (IC) with the value estimated by the Harris-Benedict (HB) formula.
  • METHODS: Eighteen patients with head and neck cancer (15 men and 3 women, mean age 57 +/- 10.7 y, age range 30-71 y) entered the study.
  • All patients were treated with radiotherapy (70.8 +/- 1 Gy, range 70-72) and received 37.4 +/- 3.5 fractions (range 32-42) and concurrent chemotherapy with cisplatinum (absolute doses of 400 to 1000 mg).
  • Measurements were done before treatment, at weeks 2, 4, and 6 of treatment, at the end of treatment, and 2 wk after treatment.
  • RESULTS: Body mass index decreased during treatment from 24.7 +/- 4.4 kg/m(2) (range 16.9-31.4) to 22.3 +/- 4.2 kg/m(2) (range 15.1-29.6).
  • REE (kcal/24 h) changed significantly during treatment (IC P < 0.05, HB formula P < 0.001).
  • REE measured by IC appeared as a U-shaped curve, but REE estimated by the HB formula decreased during treatment.
  • These differences were statistically significant before treatment, at the end of treatment, and 2 wk after treatment (P < 0.05) and showed a limited clinical agreement with the Bland-Altman method.
  • It was higher before treatment, at the end of treatment, and 2 wk after treatment.
  • [MeSH-major] Basal Metabolism. Calorimetry, Indirect / methods. Head and Neck Neoplasms / metabolism. Malnutrition / diagnosis
  • [MeSH-minor] Adult. Aged. Anthropometry. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Electric Impedance. Energy Metabolism / physiology. Female. Humans. Male. Mathematics. Middle Aged. Nutritional Requirements. Prospective Studies. Radiotherapy, Adjuvant. Weight Loss

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Malnutrition.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308133.001).
  • [ISSN] 0899-9007
  • [Journal-full-title] Nutrition (Burbank, Los Angeles County, Calif.)
  • [ISO-abbreviation] Nutrition
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


83. Field SK, Cowie RL: Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest; 2003 Oct;124(4):1482-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine.
  • BACKGROUND: Mycobacterium avium-intracellulare (MAC) causes progressive lung disease.
  • Recommended treatment regimens include a macrolide and a rifamycin, but drug intolerance and relapse after treatment is completed often limit successful therapy.
  • METHODS: Consecutive individuals referred for treatment of MAC lung disease were treated with a regimen that included either clarithromycin, 500 mg bid, or azithromycin, 250 mg/d, on weekdays; ethambutol, 15 mg/kg/d; and clofazimine, 100 mg/d.
  • The diagnosis of MAC lung disease was confirmed by multiple positive sputum culture findings in patients with typical symptoms and radiologic findings.
  • RESULTS: Thirty patients (27 women and 3 men; mean age, 70 +/- 9.4 years [SD]) were treated.
  • The remaining patients continued treatment for an average of 10 months, and sputum findings converted to negative in all 26 patients (87%).
  • One patient died of unrelated causes while still receiving therapy, and five patients (19%) relapsed an average of 17 months after treatment was completed.
  • CONCLUSIONS: Treatment with a macrolide, ethambutol, and clofazimine was successful in 20 of 30 patients (67%) with MAC lung disease and is a reasonable alternative to rifamycin-containing regimens.
  • [MeSH-major] Antitubercular Agents / therapeutic use. Clofazimine / therapeutic use. Ethambutol / therapeutic use. Leprostatic Agents / therapeutic use. Lung Diseases / drug therapy. Lung Diseases / microbiology. Mycobacterium avium-intracellulare Infection / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Therapy, Combination. Female. Humans. Macrolides / therapeutic use. Male. Middle Aged

  • Genetic Alliance. consumer health - Mycobacterium Avium Complex.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHAMBUTOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14555583.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antitubercular Agents; 0 / Leprostatic Agents; 0 / Macrolides; 8G167061QZ / Ethambutol; D959AE5USF / Clofazimine
  •  go-up   go-down


84. Morán S, Castro P, Zalaquett R, Becker P, Garayar B, José M, Li I, Jalil J, Lema G, Fajuri A, Pérez O, Martínez A, Marchant E, Chamorro G: [Treatment of advanced heart failure by heart transplantation]. Rev Med Chil; 2001 Jan;129(1):9-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of advanced heart failure by heart transplantation].
  • [Transliterated title] Tratamiento de la insuficiencia cardíaca avanzada mediante transplante de corazón.
  • BACKGROUND: Heart transplantation currently provides the most effective treatment for advanced heart failure.
  • However, medical therapy for this condition has also improved, heart donors are scarce and the cost of the procedure is high.
  • AIM: To analyze the results of 24 patients submitted to heart transplantation for end-stage heart failure needing repeated hospitalizations and i.v. inotropes for compensation.
  • PATIENTS AND METHODS: The group was comprised by 21 men and 3 women with a mean age of 36.8 years, mean left ventricular ejection fraction 19 +/- 4.5%, mean systolic pulmonary artery pressure 48 +/- 13 mmHg (24-70) and mean pulmonary vascular resistance 2.6 Wood Units (1-5).
  • Immunosuppression did not include induction therapy and steroids were discontinued early.
  • [MeSH-minor] Actuarial Analysis. Adolescent. Adult. Clinical Protocols. Disease-Free Survival. Female. Follow-Up Studies. Graft Rejection / drug therapy. Graft Rejection / immunology. Humans. Immunosuppression / methods. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11265212.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


85. Brichon PY, Boitet P, Dujon A, Mouroux J, Peillon C, Riquet M, Velly JF, Ris HB: Perioperative in-stent thrombosis after lung resection performed within 3 months of coronary stenting. Eur J Cardiothorac Surg; 2006 Nov;30(5):793-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Retrospective multi-institutional trial including all patients undergoing major lung resection (lobectomy or pneumonectomy) within 3 months of coronary stenting with non-drug-eluting stents between 1999 and 2004.
  • RESULTS: There were 32 patients (29 men and 3 women), with age ranging from 46 to 82 years.
  • The time intervals between stenting and lung surgery were <30 days, 30-60 days and 61-90 days in 22%, 53% and 25% of the patients, respectively.
  • All patients had dual antiplatelet therapy after stenting.
  • Perioperative medication consisted of heparin alone or heparin plus aspirin in 34% and 66% of the patients, respectively.
  • Twenty patients underwent lung resection after 4 weeks of dual antiplatelet therapy as recommended by the ACC/AHA Guideline Update; however, two out of three perioperative in-stent thrombosis occurred in this group of patients.
  • CONCLUSIONS: Major lung resection performed within 3 months of coronary stenting may be complicated by perioperative in-stent thrombosis despite 4 weeks of dual antiplatelet therapy after stenting as recommended by the ACC/AHA Guideline Update.
  • [MeSH-major] Coronary Disease / surgery. Coronary Thrombosis / etiology. Pneumonectomy. Postoperative Complications. Stents
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Non-Small-Cell Lung / surgery. Drug Administration Schedule. Female. Humans. Lung Neoplasms / surgery. Male. Middle Aged. Platelet Aggregation Inhibitors / administration & dosage. Postoperative Care / methods. Postoperative Period. Retrospective Studies

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2007 Jun;31(6):1149-50 [17416535.001]
  • (PMID = 16996274.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors
  •  go-up   go-down


86. Bradberry JC: Peripheral arterial disease: pathophysiology, risk factors, and role of antithrombotic therapy. J Am Pharm Assoc (2003); 2004 Mar-Apr;44(2 Suppl 1):S37-44; quiz S44-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral arterial disease: pathophysiology, risk factors, and role of antithrombotic therapy.
  • OBJECTIVE: To provide an overview of the impact of peripheral arterial disease (PAD) and the steps that can be taken to reduce its burden through greater awareness of the disease, improved diagnosis, and better treatment, with emphasis on the use of antiplatelet agents.
  • DATA SOURCES: Recent (1990-2003) published scientific literature, as identified by the author through Medline searches, using the terms peripheral arterial disease, atherothrombosis, pathophysiology, risk factors, treatment, clinical trials, and reviews on treatment.
  • DATA SYNTHESIS: PAD is a distinct atherothrombotic syndrome marked by stenosis and occlusion of peripheral arterial beds, typically those in the lower extremities.
  • IC, the most common symptom, is experienced by 2% to 3% of men and 1% to 2% of women aged 60 years and older.
  • Asymptomatic PAD, as indicated by a reduced ankle brachial systolic pressure index, should alert the health care provider to the presence of diffuse atherothrombotic disease and need for treatment.
  • The aim of pharmacotherapy is to improve the symptoms of PAD (especially IC), defer onset of limb-threatening ischemia, and improve long-term survival.
  • Successful treatment strategies include risk factor modification, particularly smoking cessation; initiation of regular exercise; control of hypertension, diabetes, and hyperlipidemia; and use of antiplatelet agents to reduce the risk of atherothrombotic events.
  • CONCLUSION: Increased awareness among members of the health care community about the prevalence of PAD and benefits associated with risk-factor reduction and antiplatelet therapy could produce substantial decreases in the burden of this disease.
  • [MeSH-major] Arteriosclerosis / drug therapy. Arteriosclerosis / pathology. Thrombosis / drug therapy. Thrombosis / pathology
  • [MeSH-minor] Angiotensin-Converting Enzyme Inhibitors / therapeutic use. Aspirin / therapeutic use. Dipyridamole / therapeutic use. Humans. Pentoxifylline / therapeutic use. Platelet Aggregation Inhibitors / therapeutic use. Randomized Controlled Trials as Topic. Risk Factors. Tetrazoles / therapeutic use. Ticlopidine / analogs & derivatives. Ticlopidine / therapeutic use

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15095934.001).
  • [ISSN] 1544-3191
  • [Journal-full-title] Journal of the American Pharmacists Association : JAPhA
  • [ISO-abbreviation] J Am Pharm Assoc (2003)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Platelet Aggregation Inhibitors; 0 / Tetrazoles; 64ALC7F90C / Dipyridamole; N7Z035406B / cilostazol; OM90ZUW7M1 / Ticlopidine; R16CO5Y76E / Aspirin; SD6QCT3TSU / Pentoxifylline
  • [Number-of-references] 50
  •  go-up   go-down


87. Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, Malcolm R, Janis GC, Markowitz JS: Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther; 2007 Mar;81(3):346-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (2) women will exhibit lower relative bioavailability of MPH than men; and (3) sex-dependent differences in subjective effects will exist. dl-MPH HCl (0.3 mg/kg) was administered orally 30 min before ethanol, 30 min after ethanol (0.6 gm/kg), or without ethanol, in a randomized, normal subject three-way crossover study of 10 men and 10 women.
  • Ethanol after or before MPH significantly (P<0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (C(max) (+/-SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration-time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2).
  • Women reported a significantly greater stimulant effect than men when questioned "Do you feel any drug effect?
  • " (P<0.05), in spite of lower mean plasma d-MPH area under the response-time curves in women.
  • Ethanol elevates plasma d-MPH C(max) and area under the concentration-time curve by approximately 40% and 25%, respectively.
  • If the poor metabolizer of MPH proves to be a distinct phenotype, determining the genetic mechanism may be of value for individualizing drug therapy.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drug Metab Dispos. 2000 Jun;28(6):620-4 [10820132.001]
  • [Cites] Expert Opin Drug Deliv. 2005 Jan;2(1):121-43 [16296740.001]
  • [Cites] Pharm Res. 2000 Apr;17(4):381-4 [10870979.001]
  • [Cites] Drug Alcohol Depend. 2002 Jul 1;67(2):149-56 [12095664.001]
  • [Cites] J Clin Psychopharmacol. 2002 Dec;22(6):633-4 [12454570.001]
  • [Cites] J Atten Disord. 2002;6 Suppl 1:S101-7 [12685524.001]
  • [Cites] Pharmacotherapy. 2003 May;23(5):609-17 [12741435.001]
  • [Cites] Pharmacotherapy. 2003 Oct;23(10):1281-99 [14594346.001]
  • [Cites] Am J Psychiatry. 2003 Nov;160(11):1909-18 [14594733.001]
  • [Cites] Am J Psychiatry. 1972 Sep;129(3):342-5 [5053717.001]
  • [Cites] J Chromatogr. 1985 Oct 11;343(2):329-38 [4066874.001]
  • [Cites] J Pharmacol Exp Ther. 1987 Apr;241(1):152-8 [3572779.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1991 Sep;30(5):773-5 [1938793.001]
  • [Cites] Life Sci. 1992;51(8):553-63 [1640806.001]
  • [Cites] Life Sci. 1994;55(7):541-50 [8041232.001]
  • [Cites] Am J Psychiatry. 1995 Nov;152(11):1652-8 [7485630.001]
  • [Cites] Psychopharmacology (Berl). 1996 Jan;123(1):26-33 [8741951.001]
  • [Cites] Ther Drug Monit. 1996 Aug;18(4):460-4 [8857569.001]
  • [Cites] Psychiatry Res. 1998 Mar 20;78(1-2):115-8 [9579707.001]
  • [Cites] Exp Clin Psychopharmacol. 1998 Nov;6(4):367-74 [9861551.001]
  • [Cites] J Clin Psychopharmacol. 1999 Aug;19(4):362-6 [10440465.001]
  • [Cites] Psychiatr Serv. 1999 Aug;50(8):1001-3 [10445644.001]
  • [Cites] J Med Chem. 2005 Apr 21;48(8):2876-81 [15828826.001]
  • [Cites] Subst Use Misuse. 2005;40(4):511-28 [15830733.001]
  • [Cites] J Clin Psychiatry. 2000 Apr;61(4):244-51 [10830144.001]
  • (PMID = 17339864.001).
  • [ISSN] 0009-9236
  • [Journal-full-title] Clinical pharmacology and therapeutics
  • [ISO-abbreviation] Clin. Pharmacol. Ther.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR01070; United States / NIAAA NIH HHS / AA / R01 AA016707; United States / NIDA NIH HHS / DA / R01 DA-15797; United States / NIAAA NIH HHS / AA / R01AA016707; United States / NIDA NIH HHS / DA / R01 DA015797; United States / NCRR NIH HHS / RR / M01 RR001070
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Central Nervous System Depressants; 0 / Central Nervous System Stimulants; 207ZZ9QZ49 / Methylphenidate; 3K9958V90M / Ethanol; 57413-43-1 / ethylphenidate
  • [Other-IDs] NLM/ NIHMS238458; NLM/ PMC3188424
  •  go-up   go-down


88. Richter WO, Jahn P, Jung N, Nielebock E, Tachezy H: Fibrinogen adsorption in the diabetic foot syndrome and peripheral arterial occlusive disease: first clinical experience. Ther Apher; 2001 Oct;5(5):335-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibrinogen adsorption in the diabetic foot syndrome and peripheral arterial occlusive disease: first clinical experience.
  • Adsorbers containing 135 ml of coupled sepharose CL-4B were used to eliminate fibrinogen from the plasma of 7 men and 3 women (48-75 years old).
  • Nine patients suffered from diabetes mellitus, 1 patient from peripheral arterial occlusive disease, and 5 patients were on regular hemodialysis.
  • Treatments were scheduled on Days 1, 2, 4, 6, 8, 10, 13, 16, 19, 22, 25, and 28.
  • One hundred forty-four treatments with fibrinogen adsorption were performed.
  • No clinical side effects due to the fibrinogen adsorption procedure were observed.
  • In these 10 patients, fibrinogen concentration before the first treatment was 473.7 +/- 183.7 mg/dl.
  • In the first treatment session, fibrinogen concentration was lowered to 241.4 +/- 125.8 mg/dl by treating 4,270 +/- 1,180 ml of plasma.
  • In the following 134 treatments, the pretreatment concentration of fibrinogen was 262.6 +/- 83.4 mg/dl, and the posttreatment concentration was 120.6 +/- 37.2 mg/dl.
  • The mean amount of plasma treated was 3,737 +/- 1,643 ml, and the mean duration of a treatment session (except first treatment) was 143.7 +/- 63.1 min.
  • During the treatment period of 28 days, wound healing was observed in 9 of the 10 patients.
  • In conclusion, affinity chromatography using the pentapeptide gly-pro-arg-pro-lys is an effective, selective, and safe procedure to lower fibrinogen concentration in plasma.
  • It could be a therapeutic option in severe blood vessel disease in which drug therapy is not sufficient and invasive procedures such as bypass or angioplasty cannot be applied.
  • [MeSH-major] Arterial Occlusive Diseases / therapy. Blood Component Removal / methods. Diabetic Foot / therapy. Fibrinogen / therapeutic use
  • [MeSH-minor] Adsorption. Aged. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Diabetic Foot.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11778917.001).
  • [ISSN] 1091-6660
  • [Journal-full-title] Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis
  • [ISO-abbreviation] Ther Apher
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9001-32-5 / Fibrinogen
  •  go-up   go-down


89. Krusche-Mandl I, Decramer A, Boltuch-Sherif J, Vlieghe E, Brands C, Vandenberghe D: [Non-tuberculous mycobacterial infections of the hand and wrist: a retrospective review of five cases from a single centre]. Handchir Mikrochir Plast Chir; 2009 Oct;41(5):283-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: A suggestion for a graduated diagnostic and therapeutic approach for patients with a suspected infection with non-tuberculous mycobacteria (NTM) of the hand and wrist is made.
  • PATIENTS AND METHODS: Between March 2003 and February 2007, 2 women and 3 men with an average age of 64 years were treated for an NTM infection of the hand and wrist.
  • Therapy consisted of immediate postoperative empirical combined drug treatment followed by antibiogram-based therapy.
  • CONCLUSION: Consideration of non-tuberculous mycobacteria in the differential diagnosis in cases of localised tenosynovitis is paramount for diagnosis.
  • Treatment based on graduated diagnostic steps, surgery and drugs (empirical followed by directed drugs) can achieve favourable clinical outcomes.
  • [MeSH-minor] Aged. Anti-Bacterial Agents / therapeutic use. Comorbidity. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Iatrogenic Disease. Male. Middle Aged. Mycobacterium marinum. Nontuberculous Mycobacteria. Opportunistic Infections / diagnosis. Opportunistic Infections / surgery

  • MedlinePlus Health Information. consumer health - Hand Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Wrist Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19790021.001).
  • [ISSN] 1439-3980
  • [Journal-full-title] Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Mikrochirurgie der Peripheren Nerven und Gefässe : Organ der Vereinigung der Deutschen Plastischen Chirurgen
  • [ISO-abbreviation] Handchir Mikrochir Plast Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


90. Tanji N, Fukumoto T, Miura N, Yanagihara Y, Azuma K, Sasaki T, Nishida T, Kikugawa T, Shimamoto K, Aoki K, Yokoyama M: Combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas in patients 80 years of age and over. Anticancer Res; 2010 Sep;30(9):3839-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas in patients 80 years of age and over.
  • BACKGROUND: This retrospective study aimed to determine the efficacy and toxicity of a combined chemotherapeutic regimen of gemcitabine and cisplatin (GC) for the treatment of metastatic urothelial carcinomas (UCs) in patients 80 years of age and over.
  • The patient cohort consisted of 9 men and 3 women, with a median age of 83 (range 80-84) years.
  • The median time to progression was 6 months, and the median overall survival was 14 months.
  • CONCLUSION: GC appears to be an effective and well-tolerated regimen for the treatment of metastatic UCs in very old patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20944180.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


91. Macon WR, Levy NB, Kurtin PJ, Salhany KE, Elkhalifa MY, Casey TT, Craig FE, Vnencak-Jones CL, Gulley ML, Park JP, Cousar JB: Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol; 2001 Mar;25(3):285-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They occurred in 11 women and 3 men with a median age of 36 years.
  • Disease distribution was primarily in the splenic red pulp and hepatic sinusoids, although liver infiltrates were largely periportal in four cases.
  • Eleven patients are dead, eight within a year of diagnosis, and two patients have maintained complete remissions after combination chemotherapy.
  • This group, along with the previously recognized gammadelta group, should be recognized as phenotypically heterogeneous subtypes of the same disease entity.
  • [MeSH-major] Liver Neoplasms / pathology. Lymphoma, T-Cell / pathology. Receptors, Antigen, T-Cell, alpha-beta / metabolism. Receptors, Antigen, T-Cell, gamma-delta / metabolism. Splenic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11224598.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


92. Marks LS: Use of 5alpha-reductase inhibitors to prevent benign prostatic hyperplasia disease. Curr Urol Rep; 2006 Jul;7(4):293-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of 5alpha-reductase inhibitors to prevent benign prostatic hyperplasia disease.
  • However, BPH disease, defined here as a life-altering urinary condition caused by BPH requiring prompt medical intervention, is a serious medical disorder associated with major complications, surgical intervention, and severe lifestyle interference.
  • BPH disease is preventable.
  • The rationale for BPH disease prevention rests on four pillars of evidence:.
  • (1) BPH disease generally is a progressive disorder;.
  • (2) complications and severe lifestyle interference from BPH disease are common and serious;.
  • (3) men at greatest risk of BPH disease can be identified using prostate-specific antigen (PSA) level higher than 1.5 ng/mL as a surrogate marker for an enlarged prostate; and (4) 5alpha-reductase inhibitors (5ARIs) reduce the primary androgen responsible for prostate growth (dihydrotestosterone), shrink the prostate, and arrest the disease process regardless of symptom status.
  • Thus, we now can identify men with an enlarged prostate at risk for BPH disease who may be candidates for preventive therapy with 5ARIs, regardless of urinary symptoms or bother.
  • [MeSH-major] 3-Oxo-5-alpha-Steroid 4-Dehydrogenase / therapeutic use. Enzyme Inhibitors / therapeutic use. Prostatic Hyperplasia / prevention & control
  • [MeSH-minor] Androgens / therapeutic use. Biomarkers. Dihydrotestosterone / therapeutic use. Disease Progression. Humans. Male. Prostate-Specific Antigen / blood. Quality of Life. United States / epidemiology. Urinary Retention / drug therapy

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Cardiol. 2002 Aug 7;40(3):567-72 [12142128.001]
  • [Cites] J Urol. 2004 Sep;172(3):915-9 [15310997.001]
  • [Cites] Eur Urol. 2003 Jul;44(1):82-8 [12814679.001]
  • [Cites] J Urol. 1968 May;99(5):639-45 [4171950.001]
  • [Cites] Eff Clin Pract. 2002 May-Jun;5(3):137-42 [12088293.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] J Urol. 2002 Jun;167(6):2484-7; discussion 2487-8 [11992063.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1399-403 [15371854.001]
  • [Cites] Br J Gen Pract. 1993 Aug;43(373):318-21 [7504499.001]
  • [Cites] Urology. 1998 Feb;51(2):237-40 [9495704.001]
  • [Cites] Urology. 1998 Mar;51(3):428-36 [9510348.001]
  • [Cites] Urology. 2000 Oct 1;56(4):610-6 [11018616.001]
  • [Cites] N Engl J Med. 1974 Oct 31;291(18):944-9 [4413434.001]
  • [Cites] Urology. 2001 Dec;58(6 Suppl 1):5-16; discussion 16 [11750242.001]
  • [Cites] Clin Prostate Cancer. 2004 Mar;2(4):228-35 [15072606.001]
  • [Cites] Urology. 1991;38(1 Suppl):4-8 [1714657.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1297-301 [15371827.001]
  • [Cites] J Urol. 2005 Jun;173(6):2040-3 [15879821.001]
  • [Cites] J Urol. 1997 Aug;158(2):481-7 [9224329.001]
  • [Cites] Urology. 1999 Mar;53(3):473-80 [10096369.001]
  • [Cites] Urology. 2003 Nov;62(5):784-5 [14624894.001]
  • [Cites] J Urol. 1997 Jan;157(1):10-4; discussion 14-5 [8976204.001]
  • [Cites] J Urol. 1993 Sep;150(3):887-92 [7688433.001]
  • [Cites] Urology. 1999 Mar;53(3):581-9 [10096388.001]
  • [Cites] Hum Pathol. 1990 Jun;21(6):578-85 [2351388.001]
  • [Cites] Urology. 2004 Apr;63(4):709-15 [15072886.001]
  • [Cites] J Urol. 1994 Aug;152(2 Pt 1):459-60 [7516980.001]
  • [Cites] J Steroid Biochem Mol Biol. 1990 Nov 20;37(3):375-8 [1701660.001]
  • [Cites] J Urol. 1999 Aug;162(2):376-82 [10411042.001]
  • [Cites] Urology. 2004 Dec;64(6):1144-8 [15596187.001]
  • [Cites] Urol Int. 2004;72(3):179-88 [15084759.001]
  • [Cites] Urology. 2001 May;57(5):999-1005 [11337315.001]
  • [Cites] N Engl J Med. 1998 Feb 26;338(9):557-63 [9475762.001]
  • [Cites] J Biol Chem. 1968 Nov 25;243(22):5953-60 [5696629.001]
  • [Cites] BJU Int. 2005 Feb;95(3):354-7 [15679793.001]
  • [Cites] J Urol. 1984 Sep;132(3):474-9 [6206240.001]
  • [Cites] Urology. 1999 Oct;54(4):662-9 [10510925.001]
  • [Cites] Urology. 2003 Jun;61(6):1086-91 [12809866.001]
  • [Cites] Curr Urol Rep. 2004 Aug;5(4):267-73 [15260926.001]
  • [Cites] J Biol Chem. 1975 Sep 25;250(18):7168-72 [240819.001]
  • [Cites] N Engl J Med. 1996 Aug 22;335(8):533-9 [8684407.001]
  • [Cites] J Urol. 1999 Apr;161(4):1174-9 [10081864.001]
  • [Cites] Urology. 2005 Jan;65(1):76-82 [15667867.001]
  • [Cites] Urology. 2003 Nov;62(5):781-3 [14624893.001]
  • [Cites] J Urol. 2005 Sep;174(3):877-81 [16093979.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):215-24 [12824459.001]
  • [Cites] J Urol. 2002 Apr;167(4):1731-3 [11912398.001]
  • [Cites] Science. 1974 Dec 27;186(4170):1213-5 [4432067.001]
  • [Cites] Urology. 1999 Mar;53(3):574-80 [10096387.001]
  • [Cites] Urology. 2002 Sep;60(3):434-41 [12350480.001]
  • [Cites] N Engl J Med. 2003 Dec 18;349(25):2387-98 [14681504.001]
  • [Cites] BJU Int. 2005 Aug;96(3):324-7 [16042723.001]
  • [Cites] Urology. 2001 Aug;58(2):210-6 [11489703.001]
  • [Cites] J Biol Chem. 1975 May 10;250(9):3498-504 [1123350.001]
  • [Cites] Urology. 2004 Sep;64(3):537-41; discussion 542-3 [15351586.001]
  • [Cites] J Androl. 1999 Jul-Aug;20(4):474-80 [10452590.001]
  • [Cites] J Biol Chem. 1976 Oct 10;251(19):5895-900 [9407.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):530-47 [12853821.001]
  • [Cites] N Engl J Med. 1992 Oct 22;327(17):1185-91 [1383816.001]
  • [Cites] Urology. 2002 Sep;60(3):464-8 [12350485.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2179-84 [15126539.001]
  • [Cites] Eur Urol. 2004 Dec;46(6):753-9 [15548443.001]
  • (PMID = 16930501.001).
  • [ISSN] 1527-2737
  • [Journal-full-title] Current urology reports
  • [ISO-abbreviation] Curr Urol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Biomarkers; 0 / Enzyme Inhibitors; 08J2K08A3Y / Dihydrotestosterone; EC 1.3.99.5 / 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 66
  •  go-up   go-down


93. Sánchez-Ortiz R, Huang SF, Tamboli P, Prieto VG, Hester G, Pettaway CA: Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol; 2005 Jun;173(6):1958-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We reviewed the records of 16 men who presented consecutively to our institution with genitourinary melanoma between 1962 and 2000.
  • In 7 patients with T1-2N0M0 disease there were no local recurrences after wide local excision (WLE) or partial penectomy at a median followup of 35 months.
  • Six of 7 men were rendered disease-free.
  • One patient died of melanoma that developed at a second primary site.
  • The 3 patients with T3 tumors who underwent partial (2) or radical (1) penectomy with or without BILND died of disease (2) or had progression (1).
  • In all patients with penile melanoma the 5-year actuarial disease specific and recurrence-free survival rates were 80% and 60%, respectively, at a median followup of 39 months (range 20 to 210).
  • Three of the 6 patients had palpable inguinal nodes, of whom 2 died after chemotherapy for unresectable disease and 1 died of other causes 51 months after negative BILND.
  • The 3 men with clinically negative groins who did not undergo prophylactic BILND had distant (1) or regional (2) metastases and died of disease.
  • In patients with scrotal melanoma the 5-year actuarial disease specific and recurrence-free survival rates were 33.3% and 33.3%, respectively, at a median followup of 36 months.
  • Patients showing clinically positive, proven metastasis died despite appropriate surgical procedures and multi-agent chemotherapy.
  • [MeSH-major] Genital Neoplasms, Male / surgery. Melanoma / surgery. Penile Neoplasms / surgery. Scrotum / surgery. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2006 Apr;175(4):1574-5; author reply 1575-6 [16516049.001]
  • (PMID = 15879790.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Kumar S, Gupta AK, Yadav BS, Ghoshal S: Primary sinonasal malignant melanoma: a clinicopathologic and prognostic study. Ear Nose Throat J; 2009 Dec;88(12):1269-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reviewed the records of 10 patients-7 men and 3 women, aged 35 to 70 years (mean: 51.4)-who had been treated at our referral center over a 9-year period.
  • The tumors were located in the nasal cavity in 7 patients and in a paranasal sinus in the other 3.
  • Medial maxillectomy was performed in 4 patients, wide local excision in 3, and endoscopic excision in 2; the remaining patient, who had presented with a liver metastasis, received chemotherapy and palliative local radiotherapy.
  • Based on the findings of our small study, we conclude that primary sinonasal malignant melanoma carries a generally poor prognosis despite aggressive treatment.
  • This finding confirms the aggressive nature of this disease.
  • [MeSH-major] Melanoma / pathology. Melanoma / surgery. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20013681.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Clayton AH, McGarvey EL, Abouesh AI, Pinkerton RC: Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. J Clin Psychiatry; 2001 Mar;62(3):185-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We examine changes in sexual functioning and depressive symptoms in patients' transition from a selective serotonin reuptake inhibitor (SSRI), which induced both a therapeutic response and sexual dysfunction, to bupropion sustained release (SR) over the course of an 8-week trial.
  • METHOD: The study included 11 adults (8 women and 3 men) who had a DSM-IV diagnosis of major depressive disorder in remission (Hamilton Rating Scale for Depression [HAM-D] score < 11) and were receiving an SSRI.
  • Depression (using the HAM-D) and sexual dysfunction (using the Changes in Sexual Functioning Questionnaire) were assessed at baseline, 2 weeks after bupropion SR was added to the current antidepressant (combined treatment), 2 weeks after taper of the SSRI was initiated and completed, and after 4 weeks of bupropion SR monotherapy.
  • CONCLUSION: Bupropion SR as a treatment for depression also alleviates sexual dysfunction due to SSRI treatment.
  • Results show that sexual functioning improves after the addition of bupropion SR to SSRI treatment and continues to improve, after discontinuation of the SSRI, with bupropion SR treatment alone.
  • [MeSH-major] Antidepressive Agents, Second-Generation / therapeutic use. Bupropion / therapeutic use. Depressive Disorder / drug therapy. Serotonin Uptake Inhibitors / adverse effects. Sexual Dysfunctions, Psychological / chemically induced. Sexual Dysfunctions, Psychological / drug therapy
  • [MeSH-minor] Adult. Cyclohexanols / adverse effects. Cyclohexanols / therapeutic use. Delayed-Action Preparations. Drug Administration Schedule. Drug Therapy, Combination. Feasibility Studies. Female. Humans. Male. Middle Aged. Sexual Behavior / drug effects. Surveys and Questionnaires. Treatment Outcome. Venlafaxine Hydrochloride

  • MedlinePlus Health Information. consumer health - Sexual Problems in Women.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Bupropion .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11305705.001).
  • [ISSN] 0160-6689
  • [Journal-full-title] The Journal of clinical psychiatry
  • [ISO-abbreviation] J Clin Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents, Second-Generation; 0 / Cyclohexanols; 0 / Delayed-Action Preparations; 0 / Serotonin Uptake Inhibitors; 01ZG3TPX31 / Bupropion; 7D7RX5A8MO / Venlafaxine Hydrochloride
  •  go-up   go-down


96. Massoll N, Mazzaferri EL: Diagnosis and management of medullary thyroid carcinoma. Clin Lab Med; 2004 Mar;24(1):49-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of medullary thyroid carcinoma.
  • Successful treatment of MTC depends heavily on early diagnosis and treatment.
  • Patients who have MEN2B or RET codon 883 or 918 mutation should have a total thyroidectomy within the first 6 months of life, preferably within the first month of life.
  • Preoperative measurement of plasma free metanephrine and neck ultrasonography always should be done if the diagnosis of MTC is known preoperatively.
  • Initial treatment of MTC is total thyroidectomy, regardless of its genetic type or putative sporadic nature, because surgery offers the only chance for a cure.
  • Treatment with 1311 has no place in the management of MTC.
  • Early thyroidectomy and appropriate management of pheochromocytoma clearly have modified the course of this disease, but more research is necessary in kindreds who have rare MTC mutations.
  • Moreover, new treatments for widespread MTC are necessary because current chemotherapy agents offer little benefit.
  • New drugs that lock the action of tyrosine kinase offer some hope.
  • [MeSH-major] Carcinoma, Medullary / diagnosis. Carcinoma, Medullary / therapy. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15157557.001).
  • [ISSN] 0272-2712
  • [Journal-full-title] Clinics in laboratory medicine
  • [ISO-abbreviation] Clin. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 143
  •  go-up   go-down


97. Hsu JT, Yeh CN, Chen YR, Chen HM, Hwang TL, Jan YY, Chen MF: Adenosquamous carcinoma of the pancreas. Digestion; 2005;72(2-3):104-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Adenosquamous carcinoma (ASC) of the pancreas is rare and correct preoperative diagnosis is difficult.
  • This study investigated the clinicopathological features of 7 cases of ASC of the pancreas and reviewed the pertinent literature to elucidate this rare disease.
  • METHODOLOGY: Seven patients (4 men and 3 women; age range 38-79 years; median 66 years) with ASC of the pancreas who underwent surgical treatment at Chang Gung Memorial Hospital between February 1993 and April 2000 were retrospectively reviewed.
  • The tumors were located at the head of the pancreas in 4 patients (57.1%), at the body in 2, and at the tail in 2.
  • Three patients received postoperative adjuvant chemotherapy.
  • Most patients had dismal prognosis despite aggressive surgery with or without adjuvant therapy.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Pancreatectomy. Pancreaticoduodenectomy. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16172546.001).
  • [ISSN] 0012-2823
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


98. Chui AK, Rao AR, Island ER, Chan HL, Leung TW, Lau WY: Multimodality tumor control and living donor transplantation for unresectable hepatocellular carcinoma. Transplant Proc; 2004 Oct;36(8):2287-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver transplantation (LT) is an acceptable mode of treatment for selected patients with unresectable hepatocellular carcinoma (HCC).
  • However, due to the scarcity of cadaveric donor organs, it is considered desirable for patients to opt for living donor liver transplantation (LDLT) or, for those not being transplanted soon, to have some form of tumor control therapy.
  • Of these, 18 recipients (15 men, 3 women) had 27 HCC.
  • Seven patients (5 LRLT, 2 cadaveric LT) were transplanted soon after listing, and thus did not require tumor control therapy.
  • Three patients underwent microwave coagulation therapy, and one had additional alcohol injections.
  • One patient received the novel PIAF (cisplatin, interferon, adriamycin, and 5-FU) chemotherapy regimen followed by selective internal irradiation (SIR) treatment.
  • One patient received conformal radiation therapy and another received SIR treatment before LT.
  • If a suitable live donor is not available, aggressive multimodality therapy is recommended while waiting for cadaveric LT.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation / methods. Liver Transplantation / physiology. Living Donors
  • [MeSH-minor] Cadaver. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Survival Analysis. Time Factors. Tissue Donors. Treatment Outcome. Waiting Lists


99. Chen MJ, Shih SC, Wang TE, Chan YJ, Chen CJ, Chang WH: Endoscopic patterns and histopathological features after eradication therapy in Helicobacter pylori-associated nodular gastritis. Dig Dis Sci; 2008 Jul;53(7):1893-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic patterns and histopathological features after eradication therapy in Helicobacter pylori-associated nodular gastritis.
  • The endoscopic finding of nodular gastritis (NG) is highly associated with presence of Helicobacter pylori infection.
  • Twenty-one adults (3 men and 18 women) with H. pylori-associated NG found on endoscopy were enrolled for this study.
  • Repeat endoscopy for the endoscopic as well as histopathological features of gastric biopsy specimens was performed 2 months later after eradication treatment. H. pylori was successfully eradicated in 19 patients.
  • After treatment, there was significant improvement in scores for gastritis activity [P < 0.001, 95% confidence interval (CI) 1.31-1.91], bacterial colonization (P < 0.001, 95% CI 0.71-1.14) and follicular gastritis (P = 0.047, 95% CI 0.04-0.52), primarily among patients whose endoscopic pattern resolved completely.
  • [MeSH-major] Gastritis / drug therapy. Gastritis / microbiology. Gastroscopy. Helicobacter Infections / drug therapy. Helicobacter pylori
  • [MeSH-minor] 2-Pyridinylmethylsulfinylbenzimidazoles / administration & dosage. Adult. Alkylating Agents / administration & dosage. Amoxicillin / administration & dosage. Anti-Bacterial Agents / administration & dosage. Anti-Ulcer Agents / administration & dosage. Biopsy. Drug Therapy, Combination. Female. Humans. Lansoprazole. Male. Middle Aged. Prospective Studies. Tinidazole / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • Hazardous Substances Data Bank. TINIDAZOLE .
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1995 Apr;48(4):325-9 [7615851.001]
  • [Cites] Helicobacter. 2006 Oct;11 Suppl 1:14-20 [16925606.001]
  • [Cites] Dig Dis Sci. 2007 Oct;52(10):2662-6 [17417730.001]
  • [Cites] J Clin Pathol. 2002 Feb;55(2):133-7 [11865009.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2701-5 [14669317.001]
  • [Cites] Virchows Arch. 2002 Apr;440(4):376-80 [11956817.001]
  • [Cites] Dig Dis Sci. 2003 May;48(5):968-75 [12772798.001]
  • [Cites] Dig Liver Dis. 2002 Nov;34(11):819-20 [12546520.001]
  • [Cites] Gut. 2004 Aug;53(8):1082-9 [15247172.001]
  • [Cites] J Med Dent Sci. 2000 Mar;47(1):39-47 [12162525.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] Hum Pathol. 1993 Jun;24(6):577-83 [8505036.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2003 Feb;36(2):217-22 [12548057.001]
  • [Cites] Helicobacter. 2002 Feb;7(1):46-52 [11886473.001]
  • [Cites] Aliment Pharmacol Ther. 1999 Mar;13 Suppl 1:13-8 [10209682.001]
  • [Cites] Gastrointest Endosc. 2001 Jan;53(1):60-4 [11154490.001]
  • (PMID = 18080192.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Alkylating Agents; 0 / Anti-Bacterial Agents; 0 / Anti-Ulcer Agents; 033KF7V46H / Tinidazole; 0K5C5T2QPG / Lansoprazole; 804826J2HU / Amoxicillin
  •  go-up   go-down


100. Pastores GM, Barnett NL, Kolodny EH: An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther; 2005 Aug;27(8):1215-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
  • BACKGROUND: The substrate synthesis inhibitor miglustat (N-butyldeoxynojirimycin) is the first oral agent to receive regulatory approval for the treatment of type I Gaucher disease (GD).
  • OBJECTIVES: The aims of this study were to further assess previous observations of the effects of miglustat in adult patients with mild to moderate type I GD and to evaluate the tolerability and safety profile of this drug.
  • METHODS: This was a noncomparative, open-label study in adult patients with type I GD (confirmed by genotyping and glucocerebrosidase assay) who were unwilling or unable to receive enzyme replacement therapy (ERT) or who had discontinued ERT for at least 3 months.
  • Patients received miglustat 100 mg TID for 12 months, with the option of continuing treatment for a further 12 months.
  • The primary end point was the percentage change in liver volume.
  • Secondary end points included the percentage change in spleen volume and changes in hematologic parameters (hemoglobin, platelets), chitotriosidase activity (a surrogate marker of disease burden), and bone assessments (dual-energy X-ray absorptiometry, magnetic resonance imaging, and radiography).
  • RESULTS: Of the 10 patients (7 men, 3 women) who received at least 1 dose of miglustat, 7 completed 24 months of treatment.
  • All patients had at least 1 manifestation of GD, including 10 with splenomegaly (mean size, 8.1 times normal; range, 3.9-15.9 times normal), 9 with thrombocytopenia, and 8 with hepatomegaly (mean size, 1.5 times normal; range, 1.0-2.0 times normal).
  • Treatment was well tolerated, and the incidence of most adverse events decreased with time.
  • Gastrointestinal and central nervous system adverse events reported during 3-month periods at the beginning (0-3 months) and end (>21-24 months) of the study were flatulence (10 and 2 patients, respectively), diarrhea (9 and 0), abdominal pain (7 and 1), tremor (4 and 1), paresthesia (3 and 0), headache (2 and 3), and abdominal distention (2 and 0).
  • CONCLUSIONS: In this small study in symptomatic adult patients with type I GD, miglustat treatment resulted in a significant decrease in liver and spleen volume at 6 and 18 months, with clinical improvement noted over 24 months.
  • The effects of treatment were consistent with those of earlier studies of miglustat in type I GD.
  • [MeSH-major] 1-Deoxynojirimycin / analogs & derivatives. Enzyme Inhibitors / therapeutic use. Gaucher Disease / drug therapy
  • [MeSH-minor] Adult. Blood / drug effects. Body Weight / drug effects. Drug Tolerance. Female. Humans. Liver / drug effects. Liver / metabolism. Male. Middle Aged. Spleen / drug effects. Treatment Outcome






Advertisement